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ABBREVIATIONS
Aa: amino acid
ABL: Abelson leukemia virus
Ac: acylcarnitine
API 2000: type of tandem mass spectrometry Applied Biosystem
BCR: breakpoint cluster region
C0: free carnitine 
CAD: collision gas
CE: collision energy
CEP: collision cell entrance potential
CI: chemical ionization
CML: Chronic Myeloid Leukemia
CUR: curtain gas
DP: declustering potential
EI: electronic ionization
EP: entrance potential
ESI: electrospray ionization
FAB: fast atom bombardment 
FP: false-positive
HPLC: high performance liquid chromatography
Ihe: interface heater
IS: ion-spray voltage
LC-MS/MS: liquid chromatography/tandem mass spectrometry
m/z: mass/charge ratio
MADD: multiple acyl-CoA dehydrogenase deficiency 
MALDI: matrix assisted laser ionization
MCADD: medium-chain acyl-CoA dehydrogenase deficiency
MMR: major molecular response 
MRM: multiple reaction monitoring
MS/MS: triple quadrupole spectrometer
MS1: first quadrupole (Q1) of a triple quadrupole analyzer
MS2: the third quadrupole (Q3) of a triple quadrupole analyzer
Q1, Q2, Q3: first, second and third quadrupole of a triple quadrupole analyzer
SCADD: short-chain acyl-CoA dehydrogenase deficiency
SD: standard deviation
TIC: total ion current
TOF: time of flight analyze
VLCAD: very long-chain acyl-CoA dehydrogenase  deficiency
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RIASSUNTO
METABOLOMICA E SPETTROMETRIA DI MASSA
Il progetto di ricerca ha avuto come obiettivo lo sviluppo di metodi di metabolomica. La 
metabolomica si propone lo studio sistematico dei metaboliti presenti in una cellula e in 
questo  campo  la  spettrometria  di  massa,  grazie  alla  sua  potenzialità  di  effettuare 
esperimenti  di  frammentazione  controllata,  gioca  un  ruolo  fondamentale  come 
metodologia d’identificazione.
Inoltre, la possibilità di accoppiare il potere risolutivo di differenti tecniche cromatografiche 
all’elevata  specificità  e  selettività  della  spettrometria  di  massa  tandem  ha  permesso 
l’enorme sviluppo della metabolomica. 
Le linee di ricerca seguite durante il progetto di dottorato sono fondamentalmente due: 
1) sviluppo di metodologie analitiche per ampliare lo spettro dei metaboliti diagnostici nello  
screening neonatale di errori congeniti del metabolismo; 
2) sviluppo di metodi analitici per l’identificazione e quantizzazione di farmaci presenti in 
concentrazioni anche molto basse in fluidi biologici.
SCREENING ALLARGATO E ERRORI CONGENITI DEL METABOLISMO
Il presente progetto di dottorato è stato condotto nel Laboratorio di Screening di Malattie  
Metaboliche  Ereditarie  del  Dipartimento  Assistenziale   di  Medicina  di  Laboratorio 
dell’Azienda Ospedaliera Universitaria “Federico II” di Napoli che, in convenzione con il  
CEINGE, da maggio 2007 ha intrapreso un progetto  pilota per lo screening neonatale 
metabolico allargato.
Lo screening neonatale consiste in una serie di esami effettuati nelle prime 48-72 ore di 
vita del bambino attraverso un’analisi LC-MS/MS: da una goccia di sangue prelevata dal  
tallone del neonato, si dosano i markers diagnostici delle varie malattie metaboliche. La 
diagnosi precoce permette d’intraprendere una terapia in grado di prevenire totalmente, o  
parzialmente, i danni provocati dalla malattia.  
Lo spettrometro su cui sono condotte le analisi è un sistema LC-MS/MS API 2000  Applied 
Biosystem.  Lo  strumento  in  questione  è  costituito  da  un  HPLC  come  sistema 
d’introduzione del campione, da un’ESI (electrospray ionization) come sorgente, un triplo  
quadrupolo come analizzatore e un rivelatore per l’elaborazione dei dati. 
Sono state sviluppate metodologie che consentono l’identificazione sullo spot di sangue di 
aminoacidi e acilcarnitine e il dosaggio quantitativo mediante l’uso di standards deuterati a  
concentrazioni note.
Nell’ambito  del  progetto  di  screening  neonatale  allargato,  che  ha  coinvolto  14  centri 
nascita campani, sono stati sottoposti a screening dal 01/05/2007 al 30/09/2011 23.753 
neonati e fra questi sono stati diagnosticati 10 casi di malattie metaboliche ereditarie:  2 
casi  di  Medium-Chain  Acyl  CoA  Dehydrogenase  Deficiency  (MCADD),  1  caso  di  β-
Ketothiolase Deficiency (BKTD), 1 caso di Short Branched Chain Amino acid Deficiency 
(SBCAD), 1 caso di Propionic Aciduria (PA), 2 casi di maternal vitamin B12 Deficiency, 1  
caso di Isovaleric Aciduria, 1 caso di Methylmalonic Aciduria e 1 caso di Isobutirryl CoA 
Dehydrogenase Deficiency. 
I casi diagnosticati hanno condotto a effettuare test genetici sulla famiglia dei neonati. In 
questo modo è stato possibile non solo avere la conferma genetica della patologia nel 
neonato, ma è stato possibile diagnosticare, nel ceppo familiare, anche i soggetti portatori 
sani della malattia genetica.
Durante  lo  svolgimento  della  tesi  è  stato  studiato  un  caso  di  deficit  di  Acil-CoA 
deidrogenasi a catena media (MCADD). Dopo la diagnosi è stata avviata per il piccolo 
paziente una terapia endovena di glucosio, come terapia d’urto della fase acuta. Le analisi  
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biochimiche e molecolari sono state estese anche ai familiari consentendo di definire che i  
parenti  del  bambino affetto  sono portatori  sani  della malattia,  eterozigoti  per  la  stessa 
mutazione. Le analisi  biochimiche e genetiche hanno inoltre permesso di  scoprire che 
anche  il  fratellino  di  15  mesi  è  affetto  dalla  stessa  patologia,  permettendo  quindi  di 
sottoporlo alle cure mediche appropriate. 
La  diagnosi  di  MCADD  in  una  fase  presintomatica  attraverso  un’analisi  LC-MS/MS, 
rispetto a una fase post-sintomatica, permette di abbattere la percentuale di coma dal 84% 
allo  0%,  la  percentuale  di  danni  neurologici  dal  40% allo  0,02%  e  la  percentuale  di 
mortalità dal 20% allo 0,02%.
MONITORAGGIO TERAPEUTICO DI FARMACI IN PAZIENTI AFFETTI DA LEUCEMIA 
MIELOIDE CRONICA
La seconda linea di ricerca, riguardante lo sviluppo di metodi analitici per il dosaggio di  
farmaci in fluidi biologici, si è focalizzata soprattutto sullo sviluppo di metodi analitici per il 
dosaggio  di  imatinib,  farmaco  usato  nel  trattamento  dei  pazienti  affetti  da  Leucemia 
Mieloide Cronica. 
La leucemia mieloide cronica (LMC) è una neoplasia maligna, causata da un’alterazione 
acquisita della cellula staminale totipotente del midollo osseo. L’anomalia genetica della 
LMC è la traslocazione cromosomica tra i cromosomi 9 e 22 che dà luogo alla formazione 
di un cromosoma 22 più corto (cromosoma Philadelphia) e dà origine a un gene ibrido, il 
gene  BCR/ABL,  che  codifica  per  un’oncoproteina  (Bcr/Abl)  con  un’attività  tirosino-
chinasica deregolata. 
Nella  cura  della  LMC è stato  fatto  un  grande  passo  avanti  nel  1998  quando  è  stato 
commercializzato l’imatinib.
L’imatinib  è  il  capostipite  di  una  nuova  classe  di  agenti  chemioterapici  che  agiscono 
inibendo enzimi ad attività tirosin-chinasica piuttosto che inibendo la rapida divisione delle 
cellule: esso agisce come un inibitore allosterico, bloccando la proteina enzimatica in una 
conformazione tale da impedire l’accesso dell’ATP al sito attivo inibendo la fosforilazione 
del substrato.
Il monitoraggio plasmatico dell’Imatinib è importante ai fini terapeutici poiché i pazienti in  
terapia, dopo 4-5 anni di trattamento, possono acquisire resistenza al farmaco; in caso di  
fallimento  della  terapia  e  comparsa  di  severi  eventi  avversi  è  importante  intervenire 
tempestivamente con l’adeguamento della dose di imatinib o con altre scelte terapeutiche 
che  si  basano  sulla  somministrazione  di  farmaci  di  II  generazione  come  nilotinib  e 
dasatinib.
Il laboratorio presso il quale si svolge il dottorato di ricerca, è inserito nel progetto EUTOS 
Imatinib BLT (Blood Level Testing) come centro di riferimento del centro-sud Italia e isole  
per il dosaggio plasmatico di imatinib.
Per il  dosaggio plasmatico di imatinib si  è messa a punto una procedura analitica che 
utilizza la LC-MS/MS. Lo spettrometro su cui si è sviluppato il metodo è uno spettrometro  
di massa a triplo quadrupolo, cioè formato da tre quadrupoli posti in serie, in cui il primo e  
il  terzo Q1 e Q3 funzionano da filtri  di  massa mentre il  secondo funziona da cella  di 
collisione. La possibilità d’impostare singolarmente i quadrupoli su determinati  range di 
massa permette un’analisi altamente selettiva e specifica.
Si effettuano delle scansioni al primo analizzatore di massa al fine di ottenere la massima 
sensibilità sul rapporto massa/carica dello ione precursore attraverso l’ottimizzazione di 
una serie di parametri strumentali.
Una volta che lo ione precursore è stato ottimizzato in termini di sensibilità e selettività, si  
procede alla sua frammentazione nella cella di collisione (Q2), in modo da stabilire i suoi 
ioni  prodotto  caratteristici.  La  scelta  degli  ioni  prodotto  è  molto  importante  poiché,  a 
determinate  condizioni,  una  molecola  frammenterà  sempre  allo  stesso  modo  e  si 
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formeranno sempre gli stessi frammenti, quindi gli ioni prodotto che si scelgono in questa  
fase  saranno  quelli  che  andranno  a  caratterizzare  la  molecola  e  a  permetterne 
l’identificazione in matrici anche molto complesse.
Una volta ottimizzati  i  parametri  per le frammentazioni  caratteristiche, si  ottimizzano le 
condizioni cromatografiche. 
Una  volta  sviluppato  e  ottimizzato  il  metodo,  si  è  passati  a  dosare  le  concentrazioni 
plasmatiche di imatinib per i pazienti arruolati nel progetto EUTOS.
I  dati  dell’Imatinib  blood  level  testing  sono  trattati  tramite  una  piattaforma  digitale,  il  
“labnet” che fa da filo diretto tra i centri ematologici associati e i centri di riferimento per il  
dosaggio dell’imatinib. 
Un ulteriore obiettivo del progetto è stata la valutazione della correlazione di due metodi 
per il dosaggio plasmatico dell’imatinib: LC-MS/MS e HPLC-UV/VIS. 
Per lo studio, è stato dosato l’imatinib plasmatico di 162 pazienti,  classificati  in cinque 
gruppi in base alla dose di imatinib giornaliera: 9 pazienti con dose da 200 mg al giorno,  
29 con dose da 300 mg, 91 con dose da 400 mg, 24 con dose da 600 mg e 9 con dose da 
800 mg. I campioni sono stati analizzati in triplicato mediante l’applicazione di entrambi i 
metodi: il coefficiente di correlazione tra i due metodi è  stato calcolato utilizzando il set 
totale dei dati e per ogni gruppo di dati corrispondenti ai cinque gruppi di pazienti. I risultati  
non  mostrano  differenze  significative  tra  i  dati  ottenuti  con  entrambi  i  metodi.  Per 
confrontare i dati ottenuti con HPLC-UV e con LC-MS/MS è stato utilizzato il metodo di  
Bland-Altman. Questo metodo prevede l’analisi grafica delle differenze tra le due tecniche 
in funzione delle medie: due metodiche sono intercambiabili allorquando le misure delle 
medie rientrino nell’intervallo “media delle differenze ± 1,96 deviazioni standard”. 
Applicando il metodo delle differenze ai risultati dei dosaggi dei 162 campioni analizzati  
con  HPLC-UV/VIS  e  LC-MS/MS,  si  dimostra  che  le  misurazioni  rientrano  nei  limiti  di  
concordabilità e che le due metodiche sono, quindi, intercambiabili. 
Nel  tempo,  sono  stati  monitorati  sei  pazienti  rilevando  la  concentrazione  plasmatica 
d’imatinib usando LC-MS/MS e la risposta molecolare (MR) per valutare la correlazione tra 
le due analisi. Dal confronto emerge che l’analisi LC-MS/MS conferma i dati della risposta 
molecolare:  in  caso  di  risposta  molecolare  maggiore,  si  riscontra  una  concentrazione 
plasmatica  d’imatinib  di  circa  1000  ng/mL  (concentrazione  ottimale);  al  contrario,  in 
assenza di  risposta  alla  terapia,  si  riscontra  una concentrazione  plasmatica  d’imatinib 
inferiore o superiore alla concentrazione plasmatica ottimale.
Durante  il  corso  di  dottorato  sono  stati  effettuati  esperimenti  per  l’identificazione  e 
quantizzazione,  tramite  un’analisi  LC-MS/MS,  dei  metaboliti  derivanti  dalla 
biotrasformazione  di  imatinib.  Studi  con  marcatura  radioattiva  hanno  dimostrato  che 
l’imatinib e il suo principale metabolita (N-demetilato) sono insieme responsabili solo del 
65% della radioattività in circolo,  quindi il  resto della radioattività è da ricondurre a un 
numero  di  metaboliti  minori  ancora  poco  caratterizzati.  Per  questo  motivo  è  stato 
sviluppato un metodo per dosare contemporaneamente l’imatinib inteso come parent drug 
e  alcuni  suoi  metaboliti  che  potrebbero  avere  un  certo  significato  se  bioattivi.  Il  
monitoraggio di nuovi biomarkers potrebbe permettere di utilizzare l’imatinib calibrandolo 
sul metabolismo individuale, in modo da massimizzare l’efficacia e minimizzare il numero 
degli effetti collaterali.
Il laboratorio presso il quale si è svolto il dottorato di ricerca è inserito anche nel protocollo 
internazionale GIMEMA (Gruppo Italiano Malattie Ematologiche dell’Adulto) CML 0408. Il 
protocollo  GIMEMA  CML  0408  è  uno  studio  sperimentale  di  fase  II,  prospettico  e 
multicentrico, per il  trattamento di prima linea della CML, BCR-ABL positiva, con i due 
inibitori  tirosino-chinasici,  imatinib e nilotinib.  L’uso di  più inibitori  in combinazione o in 
rotazione,  secondo  il  principio  di  polichemioterapia  del  cancro,  può  permettere  un 
sostanziale miglioramento del trattamento.
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Nilotinib  e  imatinib  non  sono  somministrati  insieme,  ma  secondo  un  calendario  a 
rotazione, 3 mesi nilotinib, 3 mesi imatinib, per 24 mesi (study core), e per altri 36 mesi 
(study extension) se è nell’interesse del paziente. Il nilotinib è somministrato per via orale  
due volte al giorno, per una dose totale giornaliera di 800 mg; l’imatinib è somministrato 
per via orale una volta al giorno con una dose di 400 mg.
L’obiettivo primario di tale progetto è valutare la correlazione tra la risposta ai farmaci e il  
livello plasmatico dei farmaci. A tal fine, oltre a sviluppare un metodo per il dosaggio di  
imatinib, si è sviluppato anche un metodo LC-MS/MS per il dosaggio di nilotinib. Ad oggi, i  
pazienti arruolati nello studio sono 123 ed escludendo i 23 drop out, tutti i pazienti hanno 
raggiunto i 12 mesi di trattamento. Dopo 30 giorni di trattamento con nilotinib, i pazienti  
hanno  una  concentrazione  plasmatica  media  di  2438  ng/mL;  al  giorno  90  una 
concentrazione  media  di  2625  ng/mL.  Ai  giorni  120  e  180  i  pazienti  hanno  una 
concentrazione media di imatinib rispettivamente di 1265 e 1220 ng/mL. Al giorno 270, 
dopo altri 3 mesi di trattamento con nilotinib, la concentrazione media è di 2958 ng/mL e al 
giorno  360  la  concentrazione  media  di  imatinib  è  1180  ng/mL.  Non  sono  riportate  in  
letteratura concentrazioni plasmatiche ottimali di nilotinib, mentre recenti studi riportano 
che  concentrazioni  plasmatiche  di  imatinib  leggermente  superiori  a  1000  ng/mL  sono 
associate con risposte ottimali citogenetiche e molecolari. I dosaggi di imatinib relativi al 
protocollo GIMEMA 0408 confermano che ad un anno di trattamento con somministrazioni 
a rotazione di imatinib e nilotinib la concentrazione media di imatinib è di 1180 ng/mL. 
Questo dato è molto confortante in quanto dà forza alla prospettiva ottimale dell’impiego di  
nilotinib  che  è  quella  di  utilizzare  questo  farmaco  di  nuova  generazione  non  quando 
l’imatinib ha fallito, ma di utilizzarlo prima, in modo da evitare fallimenti della terapia con 
I’imatinib e ottenere risultati a lungo termine migliori rispetto all’impiego dell’uno o dell’altro  
farmaco da soli. 
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SUMMARY
METABOLOMICS AND MASS SPECTROMETRY
The  research  project take  place  in  the  branch  of  metabolomics,  which  involves  the 
systematic study of the metabolites present in a cell and in this area MS, thanks to its  
potential  to  carry  out  controlled  experiments  of  fragmentation,  plays  a  role  as  a  key 
methodology for identification of various metabolites.
The  work  of  thesis  project  is  focused  on  the  analytical  methods  development  for  the 
diagnosis of metabolic diseases and is divided as follows:
 Newborn screening of inborn error of metabolism;
 Therapeutic drug monitoring in CML patients.
NEWBORN SCREENING OF INBORN ERROR OF METABOLISM
Newborn screening is the process by which infants are screened shortly after birth for a list 
of disorders that are treatable, but difficult or impossible to detect clinically.
The history of neonatal screening of inherited metabolic disease has seen a continuous 
and positive change limits screening to duplicate the examinative confirmation, through the 
introduction of new analytical technologies, such as tandem mass spectrometry (MS/MS), 
which allow testing not only qualitative but also quantitative. It has allowed to move from 
single  test  to  multiple  screening  tests  for  other  diseases  such  as  metabolic 
aminoacidopathies a lower incidence, organic acidurias and defects of fatty acid oxidation.
Disorders detected by most MS/MS newborn screening programs can be divided in three 
major categories:
 Amino acid disorders including urea cycle defects
 Organic acid  disorders
 Fatty acid oxidation defects
Fatty acid oxidation disorders are a group of inherited metabolic conditions that lead to an  
accumulation of fatty acids, and a decrease in cell  energy metabolism. Each fatty acid 
oxidation disorder is associated with a specific enzyme defect in the fatty acid metabolic 
pathway and affects utilization of dietary and stored fat. 
Newborn  screening  includes  testing  for  a  panel  of  acylcarnitines.  In  some  cases,  an 
elevated level of a particular acylcarnitine may indicate the possibility of one of several  
different fatty acid oxidation disorders; the specific disorder cannot be determined without 
diagnostic further testing. It has been demonstrated that the following fatty acid oxidation 
disorders may be detected in newborn dried blood spot samples using a testing panel.
Fatty acids with carbon chain lengths of primarily 18 carbons or less are metabolized in the 
mitochondria by a process known as β-oxidation. 
Several disorders in mitochondrial β-oxidation have been characterized and include very 
long-chain  acyl-CoA  dehydrogenase  (VLCAD)  deficiency,  medium-chain  acyl-CoA 
dehydrogenase  (MCADD)  deficiency,  short-chain  acyl-CoA  dehydrogenase  (SCAD) 
deficiency, multiple acyl-CoA dehydrogenase deficiency (MADD) etc. 
A pilot expanded newborn screening programme to detect inherited metabolic disorders, 
by means of liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS), 
began in the Campania region, southern Italy, in 2007. By October 2011, >23.753 dried 
blood samples on filter paper from 14 hospitals in the region had been screened in our 
laboratory.  Within this programme, we detected two cases of  Medium Chain acyl CoA 
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Dehydrogenase (MCADD) deficiency, one case of β-ketothiolase Deficiency, one case of 
Short  Branched  Chain  Amino  acid  Deficiency,  two  cases  of  maternal  vitamin  B12 
deficiency, one case of Propionic aciduria, one case of Isovaleric aciduria, one case of 
Methymlonic aciduria and one case of Isobutirryl CoA Dehydrogenase Deficiency.
In the elaborate, it is reported a clinical case describing the situation of a newborn to whom 
is diagnosed a Medium-Chain Acyl CoA Dehydrogenase Deficiency at birth. 
Immediately after the diagnosis, the patient underwent emergency therapy with glucose,  
after which the carnitine concentration decreased significantly as described in the Figure 9 
where is shown the profile of acylcarnitine during therapy.
The results of therapy are evident:  LC-MS/MS analysis shows that C0 decreases from 
0.62 µmol/L to 0.2 µmol/L , the C8 decreases from 6.14 µmol/L to 0.98 µmol/L , the C10 
decreases from 0.60 µmol/L to 0,11 µmol/L and C10: 1 decreases from 0.51 µmol/L to  
0.25 µmol/L .
The biochemical and molecular analysis are extended to family members, and in this way, 
the  early detection allows not only to discover that the relatives of affected child were 
healthy carriers of the disease, heterozygous for the mutation, but also to discover that her 
brother, one year and three months old, was affected with the same pathology,  thereby 
allowing to save the baby treating him with proper medical care.
THERAPEUTIC DRUG MONITORING IN CML PATIENTS
The second line of research has focused on the development of analytical methods for 
qualitative and quantitative assessments of drugs in biological fluids, especially on the 
assay of imatinib, a drug used to treat patients with chronic myeloid leukemia.
Chronic  Myeloid  Leukemia  (CML)  is  a  malignant  neoplasia  caused  by  an  acquired 
alteration of the totipotent stem cell of the bone marrow. The genetic abnormality of CML is 
the translocation between chromosomes 9 and 22, which causes the shaping of a shorter  
chromosome 22 (Philadelphia chromosome) and creates an hybrid gene, the BCR/ABL 
gene, which encodes an oncoprotein (Bcr/Abl) with tyrosine-kinase activity deregulated.
In  1998,  when  imatinib  was  distributed  in  the  marked,  a  great  improvement  in  the 
treatment of CML was made.
Imatinib is the first of a new category of chemotherapeutic agents that act by inhibiting 
enzymes with tyrosine-kinase activity rather than inhibiting the rapid cells division; imatinib 
acts as an allosteric inhibitor: it inhibits the substrate phosphorylation by ATP, blocking the 
enzymatic  protein  in  a  conformation  that  prevents  ATP  access  to  the  active  site.
Imatinib plasma monitoring is important for treatment because patients being treated can 
acquire resistance to the drug after 4-5 years of treatment; in case of failure of the therapy 
and occurrence of severe adverse events it is important to intervene promptly by adjusting 
the dose of imatinib or making other therapeutic choices based on the administration of II  
generation drugs such as nilotinib and dasatinib.
The doctorate was conducted in a laboratory included in the project EUTOS imatinib BLT 
(Blood Level  Testing) as reference center in  central  and southern Italy  and islands to  
evaluate plasma imatinib concentrations.
To evaluate plasma imatinib concentrations, an analytical procedure was developed that 
uses LC-MS/MS. The spectrometer on which the method has been developed is a triple 
quadrupole mass spectrometer, it consists of three quadrupoles in series, in which the first  
and third, Q1 and Q3, work as mass filters while the second acts as a collision cell. The 
possibility  to  set  individually  the quadrupoles on specifics mass range allows a highly 
selective and specific analysis.
We make  scans  of  the  first  mass  analyzer  to  obtain  the  maximum sensitivity  on  the 
mass/charge ratio of the precursor ions through the optimization of a series of instrumental  
parameters.
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Once the precursor ion was optimized in terms of sensitivity and selectivity, we proceed to 
its fragmentation in the collision cell (Q2), in order to establish its characteristic product 
ions. The choice of product ions is very important because, under certain conditions, a 
molecule fragment in the same way and they will be always the same fragments, so the 
product ions selected at this stage will be those that will characterize the molecule and will  
allow the identification in very complex matrices.
Once  optimized  the  parameters  for  the  characteristics  fragmentation,  chromatographic 
conditions are optimized too.
Once developed and optimized the method, imatinib plasma concentrations for patients  
enrolled in the EUTOS project were dosed.
Imatinib blood-level testing data are processed through a digital platform, the "Labnet" that 
acts as a direct connection between hematology centers associated and reference centers 
for imatinib dose monitoring. 
A further objective of the project was to evaluate the correlation of two methods for the 
assay  of  imatinib  plasma  concentration:  LC-MS/MS e  HPLC-UV/VIS.  So,  were  dosed 
imatinib plasma concentrations of 162 patients classified in five groups according to the 
daily dose of imatinib: 9 patients with a 200 mg daily dose, 29 with 300 mg, 91 with 400  
mg, 24 with 600 mg and 9 with 800 mg dose. The samples were analyzed in triplicate 
applying both methods: the correlation coefficient between the two methods is calculated 
using the total  set of  data for each group of  data corresponding to the five groups of  
patients. The results showed no significant differences between the data obtained applying 
both methods. The Bland-Altman method is used to compare the data obtained by HPLC-
UV and LC-MS/MS.  The Bland and Altman plot is a statistical method to compare two 
measurements techniques in clinical chemistry. The plot represents a graphical method in 
which the differences (or alternatively the ratios) between the two techniques are plotted 
against the average of the difference of the two techniques. If  the differences between 
measurements  using  the  two  assay methods lie  within  the  limits  of  agreement  of  the 
Bland–Altman test 95% of the time, this indicated that the two methods were not producing 
different results. Applying the method of differences to the dose results of the 162 samples 
analyzed by LC-MS/MS HPLC-UV/VIS it was shown that the measurements lie within the 
limits  of  agreement  and  the  two  methods  were,  therefore,  interchangeable.
Over the time, six patients were monitored detecting the plasma imatinib concentration 
using LC-MS/MS and molecular response (MR) to assess the relationship between the two 
analysis.  This  comparison  showed  that  the  LC-MS/MS  analysis  confirmed  molecular 
response data: in case of major molecular response, there was a plasma concentration of  
imatinib  of  about  1000  ng/mL  (optimal  concentration),  instead,  in  absence  of  good 
response to therapy, there was an imatinib plasma concentration lower or higher than the  
optimal one.
During  the PhD course,  experiments  have  been  undertaken for  the identification  and 
quantification of  metabolites resulting  from biotransformation of  imatinib,  through  LC-
MS/MS analysis. For this reason, a method was developed for determining simultaneously 
the imatinib parent drug and some its metabolites that may have relevance if bioactive.
The monitoring of new biomarkers could allow the use of imatinib calibrated on individual 
metabolism, in order to maximize effectiveness and minimize adverse effects.  
The laboratory, where PhD project was performed, is included in the international protocol 
GINEMA (Italian Group for Haematological Diseases) CML 0408. The Protocol GINEMA 
CML 0408 is an experimental study of phase II, for the first-line treatment of CML, BCR-
ABL positive, with two tyrosine-kinase inhibitors: imatinib and nilotinib.  
Nilotinib and imatinib don’t were given together, but according to a schedule rotation, 3 
months nilotinib, 3 months imatinib, for 24 months (core study), and for other 36 months 
(study extension) if the patient was interested to continue.
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The nilotinib was administered orally twice a day, for a total daily dose of 800 mg. Imatinib 
was given orally once daily with a dose of 400 mg.  The primary objective of this project 
was to evaluate the correlation between drug response and the plasma level of drugs. 
For this purpose, in addition to developing a method for determination of imatinib,  it was 
also developed a LC-MS/MS method for the dosage of nilotinib.  To date, 123 patients 
enrolled  in  the  study,  excluding  23 dropouts,  all  patients  have reached 12 months  of  
treatment.  After  30  days  of  treatment  with  nilotinib,  patients  had  a  plasma  mean 
concentration of 2438 ng/Ml; at day 90 they had a mean concentration of 2625 ng/mL. At 
days 120 and 180, patients had a mean concentration of imatinib, respectively 1265 and 
1220 ng/mL. At 270 day, after 3 months of treatment with nilotinib, mean concentration 
was 2958 ng/mL and at day 360, mean concentration of imatinib was 1180 ng/mL. Optimal 
concentrations of nilotinib were not reported in the literature, while recent studies showed 
that imatinib plasma concentrations slightly higher than 1000 ng/mL were associated with 
cytogenetic and molecular responses optimal. The dosages of imatinib for the GIMEMA 
0408 protocol, confirmed that, after a year of treatment with rotating doses of imatinib and  
nilotinib,  imatinib  mean  concentration  was  1180  ng/mL.  This  information  was  very 
encouraging because it has given strength to the best perspective of the nilotinib use: to 
use this next generation drug not when imatinib has failed, but using it before, in order to 
avoid treatment failures with imatinib and achieve long-term results better than using a 
single type of drug.
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Chapter 1
METABOLOMICS AND MASS SPECTROMETRY
1.1 Metabolomics
Metabolomics  is  the  scientific  study  of  chemical  processes  involving  metabolites. 
Specifically, metabolomics is the "systematic study of the unique chemical fingerprints that 
specific  cellular  processes leave  behind",  the  study of  their  small-molecule  metabolite  
profiles [1]. The metabolome represents the collection of all metabolites in a biological cell,  
tissue, organ or organism, which are the end products of cellular processes. Thus, while 
mRNA gene expression data and proteomic analyses do not tell the whole story of what 
might be happening in a cell, metabolic profiling can give an instantaneous snapshot of the 
physiology of that cell. One of the challenges of systems biology and functional genomics  
is  to  integrate  proteomic,  transcriptomic,  and  metabolomic  information  to  give  a  more 
complete picture of living organisms. Therefore, changes observed in the transcriptome or 
in the proteome do not always correspond to phenotypic alterations (Figure 1). The idea 
that biological fluids reflect the health of an individual has existed for a long time. The 
concept that individuals might  have a “metabolic profile”  that  could be reflected in the 
makeup of their biological fluids was introduced by Roger Williams in the late 1940s [2], 
who used paper chromatography to suggest characteristic metabolic patterns in urine and 
saliva were associated with diseases such as schizophrenia. However, it was only through 
technological  advancements  in  the  1960s  and  1970s  that  it  became  feasible  to 
quantitatively (as opposed to qualitatively) measure metabolic profiles. 
Metabolites  are  the  intermediates  and  products  of  metabolism.  Within  the  context  of 
metabolomics, a metabolite is usually defined as any molecule less than 1 kDa in size [3]. 
In  human-based  metabolomics,  it  is  common to  describe  metabolites  as  being  either 
endogenous  (produced  by  the  host  organism)  or  exogenous.  Metabolites  of  foreign 
substances such as drugs are termed xenometabolites. The metabolome forms a large 
network of metabolic reactions, where outputs from one enzymatic chemical reaction are 
inputs to other chemical reactions. 
Analysis of cellular function at the molecular level requires recruitment of several different  
analytical techniques. Whereas comprehensive methods for analysis at the transcriptional 
level (transcriptome) and at the translational level (proteome) are currently in a rapid state 
of development, and high throughput analytical methods are already in use [4] [5] [6].
Mass spectrometry is the most frequently employed method of detection in the analysis of  
the metabolome. The most important advantages of MS are its high sensitivity, selectivity 
and  “high-throughput”  in  combination  with  the  possibility  to  confirm the  identity  of  the 
components present in the complex biological samples as well as the detection and, in 
most  of  the  cases,  the  identification  of  unknown  and  unexpected  compounds. 
Furthermore, the combination of the separation techniques (e.g.,  chromatography)  with 
MS  tremendously  expands  the  capability  of  the  chemical  analysis  of  highly  complex 
biological samples. Usually, the MS applications are distinguished in three basic groups: 
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small  metabolites  such  as  organic  acids,  amino  acids,  fatty  acids,  steroids  and  their 
conjugates;  peptides,  proteins  and  glycoproteins  and  oligonucleotides  derived  from 
biopolymers (DNA, RNA).
Figure 1. The complex interrelationship between the genome, transcriptome (RNA molecules), proteome (proteins) and metabolome 
(metabolites that exist in any metabolic and environmental state). Alterations in any of these levels of control might influence 
the final phenotype.
1.2 Metabolome analysis
For  analysis  of  metabolome,  there  are  basically only  two  different  strategies:  target 
analysis  and metabolite  profiling.  Generally,  target  analysis  is  restricted to  quantitative 
analysis of a class of compounds that are related to a specific pathway or to intersecting 
pathways. Targeted analysis is very useful for the study of the primary effect of a genetic 
alteration,  and  the  analytical  procedures  must  include  identification  and  absolute 
quantification of the selected metabolites in the sample. Metabolite profiling or metabolic 
profiling  involves  rapid  analysis,  often  not  quantitative,  of  a  large  number  of  different  
metabolites with the objective to identify a specific metabolite profile that characterizes a  
given sample. This approach can be sub-divided into:
- Metabolic fingerprinting 
- Metabolic footprinting
Fingerprinting covers the scanning of a large number of intracellular metabolites detected 
by a selected analytical technique or by a combination of different techniques in a defined  
situation [7]. Not all metabolites must be identified and quantified, and “raw” data can be 
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used; i.e., one may use the information content from mass spectrometry (MS) profiles or 
nuclear  magnetic  resonance  (NMR)  spectra  directly,  but  the  method  must  give  a 
reproducible profile of the sample.
Metabolic footprinting is more recently proposed approach, which is technically similar to 
finger printing, but is focused on the measurements of all extracellular metabolites present 
in a spent culture medium. The compounds determined are metabolites secreted by the 
cells  into  the  medium and the  medium components  biochemically  transformed by the 
organism.
Mass spectrometry and NMR are the most frequently employed methods of detection in 
the analysis of the metabolome.
NMR in particular, is very useful for structure characterization of unknown compounds and 
has been applied to the analysis of metabolites in biological fluids and cells extracts [8]. 
It is also low sensitivity and the equipment costs are much higher compared to MS based  
techniques. The most important advantages of MS are its high sensitivity, selectivity and 
high-throughput  in  combination  with  the  possibility  to  confirm  the  identity  of  the 
components present in the complex biological samples as well as the detection and, in 
most of the cases, the identification of unknown and unexpected compounds. Since the 
ordinary mass spectrometry is  quite  limited in  the analysis  of  mixtures of  compounds,  
combined methods have been developed, where mass spectrometers are were coupled to 
efficient  separation  devices,  such as  gas chromatography (GC)  and  high-performance 
liquid  chromatography (HPLC).  In  the  experimental  work  of  this  thesis  we  have  used 
HPLC.
1.3  Mass spectrometry for metabolomics
3.1.1  Instrumentation
Mass Spectrometry (MS) is  an analytical  technique that  measures the mass-to-charge 
(m/z) ratio of  charged particles. MS is an analytic  method that employs ionization and 
mass analysis of compounds in order to determine the mass, formula and structure of the  
compound  being  analyzed.  The  technique  has  both  qualitative  and  quantitative  uses. 
These include identifying unknown compounds, determining the isotopic composition of 
elements in a molecule, and determining the structure of a compound by observing its 
fragmentation.  MS  is  now  in  very  common  use  in  analytical  laboratories  that  study 
physical, chemical, or biological properties of a great variety of compounds. It is used for  
determining masses of particles, for determining the elemental composition of a sample or 
molecule, and for elucidating the chemical structures of molecules, such as peptides and 
other chemical compounds.
All this can be done with very limited amount of sample (in some cases less than a ρg) at 
very low concentrations in complex mixtures. The mass spectrometry is used to measure 
the mass of a molecule after it is ionized, that is which has been given an electric charge. 
In fact, that which is measured is the m/z ratio of ions that are formed; the charge, in fact,  
being expressed as the number z of elementary charges (those possessed by an electron 
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or a proton), the measure unit is Da/z. A Dalton (Da) is 1/12 the mass of an atom carbon 
(12C) and is the measure unit currently used to express the mass of molecules (too small  
entities because they use the grams). 
The technique consists in the transformation of the sample into ions, in their separation 
according to their mass ratio of charge (m/z) and in their detection.
In Figure 2 we can see the scheme that represents the different parts of a generic mass 
spectrometer [9].
Figure 2. General components of mass spectrometers.
The sample, which can be a solid, liquid or gas, is introduced in a atmospheric pressure or  
vacuum chamber, before being ionized. The purpose of the introduction system is to allow 
the input,  in the ion source, an appropriate amount of  sample without,  thereby,  cause 
significant loss of vacuum. The introduction of the analyte can occur by direct infusion or 
by connecting the mass spectrometer to a chromatographic system (Gas Cromatoraphy - 
GC or High Performance Liquid Cromatography - HPLC). Several different types of ion 
sources  are  commonly  used  for  LC/MS;  each  is  suitable  for  different  classes  of 
compounds. Independently of the introduction system and ionization techniques used, the 
sample may already exist in ionic form in solution, or it can be ionized simultaneously to its  
volatilization.
These ions, which are found in the gas phase, are separated in the analyzer according to  
their mass/charge ratio, and then collected by a detector. In the detector, they generate an 
electrical signal proportional to the number of present ions. The data processing system 
records these electrical signals according to their m/z ratio and converts them into a mass 
spectrum.
In synthesis, the processes that take place in a mass spectrometer are:
 production and fragmentation of ions;
 separation of ions according to mass/charge ratio;
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 detection of ions.
A mass spectrometer is an instrument that work under high vacuum conditions (10 -7 Torr) 
in all components of the instrument, except in the detector and the viewer the signal.
The appearance of the mass spectrum for a given species is strictly related to the method 
used for the formation of ions.
Techniques for ionization have been key to determining what types of samples can be 
analyzed by mass spectrometry. The types of ion sources may be divided into two main 
categories: 
  Source in gas phase
- Electron Ionization (EI)
- Chemical Ionization (CI) 
- Atmospheric Pressure Chemical Ionization (APCI)
in which the sample is first evaporated and the gaseous components are then ionized in 
various ways.
Desorption ionization techniques
- Fast Atom Bombardment (FAB)
- Thermospray
- Matrix Assisted Laser Desorption Ionization (MALDI)
- Electrospray Ionization (ESI)
which do not require total vaporization of the sample. The main advantage of the ionization 
desorption is the fact that it allows the analysis of non-volatile molecules and low thermal  
stability.
1.1.1 Electron Ionization
In  many  studies,  "EI"  is  used  as  an  abbreviation  of  "electron  impact".  Actually  this 
attribution is not exactly correct, because the electrons, without mass, not "impact" with the 
molecules or atoms, but "interact" with them [10].
In fact, when an electron passes through to a molecule, is established a mechanism of  
energy transfer to obtain the extraction of one or more electrons form the outer valence 
levels, more rarely, by a process one hundred times less efficient. It is possible that the 
electron is captured by the molecule thus creating a negative ion. The curves representing 
the ionization efficiency of a beam electronic energy function change from molecule to 
molecule.  If  the  energy transferred  to  the  molecules  is  greater  than necessary for  its  
ionization, the phenomenon of fragmentation can occur, so ion splits into one or more 
parties creating new ions, the so-called product ions, or neutral particles.
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This technique of ionization is called hard because the high energy provided to precursor  
ions cause its fragmentation and thus the "destruction", leading to very complicate mass 
spectra.
Since, in reproducible conditions, the process of fragmentation of an ion is always the 
same, the profile of the mass spectrum turns out to be a reliable "fingerprint digital" for the 
recognition of the compound.
The electron impact ionization is generally obtained through the interaction between the 
sample, gaseous or vaporized, and a flow of electrons emitted from a filament tungsten or 
rhenium,  which  is  rendered incandescent  by the passage of  a  current.  The impact  of  
electrons with molecules of the analyte produces a mixture of positive ions begin to be 
accelerated toward the separation chamber by an electric field appropriately calibrated 
[11].
Primary products are, therefore, positive ions with a unit charge, and the proximity of high-
energy electrons to molecules is such as to cause the loss of electrons per  repulsion 
electrostatic:
M + e - → M · +  + 2e -
where, M represents the molecule of the analyte, while M • + is its molecular ion, which is a 
radical ion, with the same molecular weight of the molecule.
1.1.2  Chemical Ionization 
Chemical  ionization (CI)  is a lower energy process than electron ionization. The lower 
energy yields less fragmentation, and usually a simpler spectrum. A typical CI spectra has 
an easily identifiable molecular ion. In a CI experiment, ions are produced through the 
collision of the analyte with ions of a reagent gas that are present in the ion source. Some 
common reagent gases include: methane, ammonia, and isobutane. Inside the ion source, 
the reagent gas is present in large excess compared to the analyte. Electrons entering the 
source will preferentially ionize the reagent gas. The resultant collisions with other reagent 
gas molecules will create an ionization plasma (in physics and chemistry, plasma is a state 
of matter similar to gas in which a certain portion of the particles are ionized. Heating a gas 
may ionize its molecules or atoms, thus turning it into a plasma, which contains charged 
particles: positive ions and negative electrons). Positive and negative ions of the analyte  
are formed by reactions with this plasma.
1.1.3 Electrospray Ionization 
Electrospray ionization (ESI) is an ionization technique for small amounts of large and/or  
labile  molecules  such  as  peptides,  proteins,  organometallics,  and  polymers.  The  ESI 
source operates at atmospheric pressure. A sample solution is sprayed from a small tube 
into a strong electric field in the presence of a flow of warm nitrogen to assist desolvation. 
The typical solvents for electrospray ionization are prepared by mixing water with volatile  
organic compounds (e.g. methanol, acetonitrile).The droplets formed evaporate in a region 
maintained at a vacuum of several Torr causing the charge to increase on the droplets. To  
decrease the initial  droplet  size, compounds that  increase the conductivity  (e.g.  acetic 
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acid) are 
customarily added to the solution. The aerosol is sampled into the first vacuum stage of a  
mass  spectrometer  through  a  capillary,  which  can  be  heated  to  aid  further  solvent  
evaporation from the charged droplets. The solvent evaporates from a charged droplet  
until it becomes unstable upon reaching its Rayleigh limit. At this point, the droplet deforms 
and emits charged jets in a process known as Coulomb fission. The multiply charged ions 
then enter the analyzer (Fig.3). The most obvious feature of an ESI spectrum is that the 
ions carry multiple charges, which reduces their mass-to-charge ratio compared to a singly 
charged  species.  This  allows  mass  spectra  to  be  obtained  for  large  molecules. 
Electrospray ionization is the ion source of choice to couple liquid chromatography with  
mass spectrometry.
Figure 3. Formation of ions of the analyte in the ESI system.
1.1.4 Atmospheric Pressure Chemical Ionization 
Atmospheric-pressure chemical ionization (APCI) is a form of chemical ionization which 
takes place at atmospheric pressure. Typically the mobile phase containing eluting analyte 
is heated to relatively high temperatures (above 400 degrees Celsius), sprayed with high 
flow rates of nitrogen and the entire aerosol cloud is subjected to a corona discharge that  
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creates ions. The ionization occurs in the gas phase, unlike ESI,  where the ionization 
occurs in the liquid phase. A potential advantage of APCI is that it is possible to use a 
nonpolar  solvent  as a  mobile  phase solution,  instead of  a  polar  solvent,  because the 
solvent and molecules of interest are converted to a gaseous state before reaching the 
“corona discharge” pin (Fig.4). Typically,  APCI is a less "soft" ionization technique than 
ESI, i.e. it generates more fragment ions relative to the parent ion.
1.3.1.5 Mass analyzers
Mass analyzers separate the ions that are formed in the source according to their mass-to-
charge ratio.  There are many types of  mass analyzers,  using either  static or dynamic  
fields, and magnetic or electric fields, but all operate according to the above differential 
equation.  Each  analyzer  type  has  its  strengths  and  weaknesses.  Many  mass 
spectrometers use two or more mass analyzers for tandem mass spectrometry (MS/MS). 
They are:
- Magnetic Analyzer (the ions are separated by charge to mass ratios)
- Quadrupole (mass analyzer that uses an electric field to separate ions)
- Time-of-flight  (separate  ions  by time without  the  use of  an  electric  or 
magnetic field)
- Ion trap (it uses an electric field for the separation of the ions  by mass to 
charge ratios)
- Fourier  transform-ion  cyclotron  resonance  (FT-ICR  or  FT-MS)  (Ions 
entering a chamber are trapped in circular orbits by powerful  electrical 
and magnetic fields. When excited by a radio-frequency (RF) electrical 
field,  the  ions  generate  a  time-dependent  current.  This  current  is 
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converted by Fourier transform into orbital frequencies of the ions which 
correspond to their mass-to-charge ratios).
1.3.1.5.1 Magnetic analyzer
A sector field mass analyzer uses an electric and/or magnetic field to affect the path and/or 
velocity of the charged particles in some way. As shown above, sector instruments bend 
the trajectories of the ions as they pass through the mass analyzer,  according to their 
mass-to-charge ratios, deflecting the more charged and faster-moving, lighter ions more. 
The analyzer can be used to select a narrow range of m/z or to scan through a range of 
m/z to catalog the ions present [12].
1.1.5.2 Quadrupole mass analyzer
The quadrupole consists of four parallel metal rods. Each opposing rod pair is connected 
together electrically, and a radio frequency (RF) voltage is applied between one pair of 
rods and the other. A direct current voltage is then superimposed on the RF voltage. Ions  
travel down the quadrupole between the rods. Only ions of a certain mass-to-charge ratio  
m/z  will  reach  the  detector  for  a  given  ratio  of  voltages:  other  ions  have  unstable 
trajectories and will collide with the rods. This permits selection of an ion with a particular  
m/z or allows the operator to scan for a range of m/z-values by continuously varying the 
applied voltage.
1.3.1.5.3  Time-of-flight analyzer
The time-of-flight (TOF) analyzer uses an electric field to accelerate the ions through the 
same potential, and then measures the time they take to reach the detector. If the particles 
all have the same charge, the kinetic energies will  be identical, and their velocities will  
depend only on their masses. Lighter ions will reach the detector first.
1.3.1.5.4   Ion trap
The quadrupole ion trap works on the same physical principles as the quadrupole mass 
analyzer, but the ions are trapped and sequentially ejected. Ions are trapped in a mainly 
quadrupole RF field, in a space defined by a ring electrode (usually connected to the main 
RF potential) between two endcap electrodes (typically connected to DC or auxiliary AC 
potentials). The sample is ionized either internally (e.g. with an electron or laser beam), or 
externally, in which case the ions are often introduced through an aperture in an endcap 
electrode.
There are many mass/charge separation and isolation methods but the most commonly 
used is the mass instability mode in which the RF potential is ramped so that the orbit of 
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ions with a mass a > b are stable while ions with mass b become unstable and are ejected  
on the z-axis onto a detector. There are also non-destructive analysis methods.
1.1.5.5 Fourier transform-ion cyclotron resonance
Fourier  transform ion  cyclotron  resonance  mass  spectrometry,  also  known  as  Fourier 
transform mass spectrometry, is a type of mass analyzer for determining the m/z ratio  of  
ions based on the cyclotron frequency of the ions in a fixed magnetic field. The ions are  
trapped in a Penning trap (a magnetic field with electric trapping plates) where they are 
excited to  a larger  cyclotron  radius by an oscillating electric  field  perpendicular  to  the 
magnetic field. The excitation also results in the ions moving in phase (in a packet). The 
signal is detected as an image current on a pair of plates which the packet of ions passes  
close to  as they cyclotron.  The resulting signal  is called a free induction decay (FID), 
transient or interferogram that consists of a superposition of sine waves. The useful signal  
is extracted from this data by performing a Fourier transform to give a mass spectrum.
Fourier  transform ion  cyclotron  resonance  (FTICR)  mass  spectrometry  is  a  very  high 
resolution technique in that masses can be determined with very high accuracy.
1.1.6 Detectors
The final element of the mass spectrometer is the detector. The detector records either the 
charge induced or the current produced when an ion passes by or hits a surface. In a  
scanning instrument, the signal produced in the detector during the course of the scan 
versus where the instrument is in the scan (at what m/z) will produce a mass spectrum, a  
record of ions as a function of m/z.
Typically,  some  type  of  electron  multiplier  is  used,  though  other  detectors  including 
Faraday cups and ion-to-photon detectors are also used. Because the number of ions 
leaving  the  mass  analyzer  at  a  particular  instant  is  typically  quite  small,  considerable 
amplification is often necessary to get a signal. In fact, a photomultiplier electronic records 
the  weak  current  produced  by  ions  that  have  passed  the  analyzer,  amplifies  it  and 
converts it into a signal which is then transmitted to a computer equipped with software  
that will give us the final mass spectrum.
1.1.7 Mass spectrum
A mass spectrum is an intensity m/z (mass-to-charge ratio) plot representing a chemical 
analysis. Hence, the mass spectrum of a sample is a pattern representing the distribution 
of  ions  by mass (more  correctly:  mass-to-charge ratio)  in  a  sample.  It  is  a  histogram 
usually acquired using a mass spectrometer. Not all mass spectra of a given substance 
are the same. For example some MS break the analyte molecules into fragments; others  
observe  the  intact  molecular  masses  with  little  fragmentation.  A  mass  spectrum  can 
represent many different types of information based on the type of mass spectrometer and 
the specific experiment applied; however, all plots of intensity versus mass-to-charge are 
referred to as mass spectra. 
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The x-axis of a mass spectrum represents a relationship between the mass of a given ion 
and the number of elementary charges that it carries.
The  y-axis  of  a  mass  spectrum  represents  signal  intensity  of  the  ions.  When  using 
counting detectors the intensity is often measured in counts per second (cps). When using 
analog detection electronics the intensity is typically measured in volts.
2.3.2 Chromatographic techniques and interfacing
MS  is  employed  in  combination  with  prefractionation  methods  such  as  gas 
chromatography (GC), liquid chromatography (LC) and capillary electrophoresis (CE) to 
reduce the complexity of target samples before MS analysis. GC coupled to MS has been 
extensively used in metabolome analysis because of its high separation efficiency that can 
resolve  very  complex  biological  mixtures.  Only  volatile  compounds  like  ketones  and 
alcohols can be examined directly by GC-MS. Analysis of semi-volatile compounds such 
as amino acids and lipids require additional chemical derivation process; this step adds 
time to the analysis as well as causes more complex sample-handling and an increased 
variance  in  the  analysis.  Furthermore,  heat-labile  compounds  can’t  be  analyzed  and 
identification  of  unknown  derivatized  compounds  can  be  difficult  because  they  are 
chemically  modified  [7]  [13].  By  combining  MS  with  LC,  molecular  identification  and 
quantification of polar,  less-polar and neutral  metabolites can be achieved, even when 
they are present at relatively low concentrations levels and in a complex matrix. 
LC-MS can provide information on analytes that display chemical diversities, are labile or 
are difficult to separate at the preparative scale. By using LC-MS, known and unknown 
compounds that are present in a biological matrix can be detected and identified without 
any prior knowledge of their exact chemical structure. LC-MS is therefore an important tool  
for  metabolite  profiling.  CE  is  a  powerful  technique  for  the  separation  of  charged 
metabolites,  offering  high-analyte  resolution.  The  combination  whit  mass  spectrometry 
makes CE-MS an ideal tool for the analysis of the metabolome [7][13][14]. 
1.3.3 Tandem MS
Tandem mass spectrometry (MS/MS) was developed over 20 years ago [15] and was first  
applied to biochemical genetics soon afterwards.
The technique is most commonly performed using a triple quadrupole mass spectrometer 
which  comprises  an  ionization  source,  three  mass  filters  connected  in  tandem and  a 
photomultiplier detector (Fig.5).
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Figure 5. Tandem MS scheme.
Ions  produced  in  the  source  are  selected  by  the  first  quadrupole  (MS1)  for  the 
transmission to the second quadrupole,  which is designed as the collision cell.  In this  
region, the ions are accelerated and collide with molecules of an inert collision gas (usually 
argon)  and  undergo  collision-induced  dissociation  (CID).  The  fragments  produced  are 
transmitted to the final quadrupole (MS2) where they are again selected for transmission 
to the detector.  Ions transmitted by MS1 to the collision cell  are called precursor ions 
(formerly referred to as “parent” ions), and the fragments produced from CID are product 
ions (formerly “daughter” ions) [16].
Multiple stages of mass analysis  separation can be accomplished with individual mass 
spectrometer elements separated in space or using a single mass spectrometer with the 
MS steps separated in time.
In  MS-MS  in  space,  the  separation  elements  are  physically  separated  and  distinct, 
although there is a physical connection between the elements to maintain high vacuum. 
These elements can be sectors, transmission quadrupole, or time-of-flight. 
By doing tandem mass spectrometry in time, the separation is accomplished with ions 
trapped in the same place, with multiple separation steps taking place over time.
MS/MS can be used for analysis of complex mixtures with little or no sample clean up. 
It allows rapid analysis time, typically around 2-3 min per sample. The methodology does  
have limitations, however: it cannot separate isomers and, in complex biological mixtures,  
the likelihood of encountering more than one compound with the same molecular weight  
and producing the same fragments is sometimes high.
An important application using tandem mass spectrometry is in protein identification. It is  
more sensitive,  specific,  reliable,  and comprehensive than traditional  assays,  into  their 
newborn-screening  programs.  MS/MS  is  rapidly  replacing  these  one-analysis,  one-
metabolite,  one-disease  classis  screening  techniques  with  a  one-analysis,  many-
metabolities, many-diseases approach that also facilitates the ability to add new disorders 
to existing newborn-screening panels.
1.4 Objectives of research project
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My  project  will  then  take  place  in  the  branch  of  metabolomics,  which  involves  the 
systematic study of the metabolites present in a cell and in this area MS due to its potential 
to carry out controlled experiments of fragmentation, plays a role as a key methodology for 
identification of various metabolites.
The work of thesis project is focused on the analytical methods development for the 
diagnosis of metabolic diseases and is divided as follows:
 Newborn screening of inborn error of metabolism;
 Therapeutic drug monitoring in CML patients.
25
Chapter 2 
NEWBORN SCREENING OF INBORN ERROR OF METABOLISM
INTRODUCTION
2.1 NEWBORN SCREENING
Newborn screening is the process by which infants are screened shortly after birth for a list 
of  disorders that are treatable,  but difficult  or  impossible to detect clinically.  Screening 
programs are often run by state or national governing bodies with the goal of screening all  
infants born in the jurisdiction. Newborn screening originated in the 1960s when Robert  
Guthrie developed a method to screen for phenylketonuria,  a disorder which could be 
managed by dietary adjustment if diagnosed early [17]. Whole blood samples are collected 
from the infant's heel on specially designed filter paper, and then tested for a panel of 
disorders. The disorders tested can vary from region to region, based on funding and the 
prevalence of a condition in the population. 
Universal newborn screening (NBS) aims to identify infants that appear healthy at birth,  
but  are  afflicted  with  conditions  that  can  cause  severe  illness  or  death.  With  early 
detection, these conditions can be managed to prevent complications.
The history of neonatal screening of inherited metabolic disease has seen a continuous 
and positive change limits screening to duplicate the examinative confirmation, through the 
introduction of new analytical technologies, such as tandem mass spectrometry (MS/MS), 
which allow testing not only qualitative but also quantitative. It has allowed to move from 
single  test  to  multiple  screening  tests  for  other  diseases  such  as  metabolic 
aminoacidopathies a lower incidence, organic acidurias and defects of fatty acid oxidation.
Newborn screening tests are most commonly done from whole blood samples collected on 
specially  designed filter  paper.  The filter  paper  is  often  attached to  a form containing 
required information about the infant and parents. This includes date and time of birth, 
date and time of sample collection, the infant's weight and gestational age. The form will  
also  have  information  about  whether  the  baby  has  had  a  blood  transfusion  and  any 
additional  nutrition  the  baby  may  have  received.  Most  newborn  screening  cards  also 
include contact information for the infant's physician in cases where follow up screening or 
treatment is needed (Fig.6).
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Figure 6. Impregnation of blood from the heel of a newborn into a filter paper card.
Ideally, newborn screening samples are collected from the infant between 24 hours and 7 
days after birth. Samples can be collected at the hospital, or at the screening center.
Disorders detected by most MS/MS newborn screening programs can be divided in three 
major categories [18]:
 Amino acid disorders including urea cycle defects
 Organic acid  disorders
 Fatty acid oxidation defects
2.1.1 Disorders of amino acid metabolism
Aminoacidopathies involve an inherited deficiency of an enzyme or transport system that 
mediates  the  metabolism  of  a  particular  amino  acid.  As  a  result,  the  amino  acid  
accumulates and evokes a toxicity syndrome that commonly extends to the CNS (Central 
Nervous System). The severity of the clinical picture depends on the amino acid involved,  
the duration of its accumulation and the supervention of other medical complications.
Tandem mass spectrometry technology can measure the amount of various amino acids 
present in the blood spot. The amino acids on the panel were chosen for their ability to  
indicate the presence of specific disorders. In general, they should be detectable after 24 
hours of age despite feeding status and, when disease is present, will continue to increase 
with time. The presentation of primary disorders of amino acid metabolism in general is 
insidious  and  slow,  and  patients  do  not  commonly  have  major  metabolic 
decompensations. However, when untreated, the symptoms may present to neurologist as 
ataxia, mental retardation and seizures. Treatment consist of limiting the offending amino 
acid in the diet.
1.1.2 Fatty acid and organic acid disorders
Fatty acid oxidation disorders are a group of inherited metabolic conditions that lead to an  
accumulation of fatty acids, and a decrease in cell  energy metabolism. Each fatty acid 
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oxidation disorder is associated with a specific enzyme defect in the fatty acid metabolic 
pathway and affects utilization of dietary and stored fat. 
In  chemistry,  especially  biochemistry,  a  fatty  acid  is  a  carboxylic  acid  with  a  long 
unbranched aliphatic tail (chain), which is either saturated or unsaturated. Most naturally 
occurring fatty acids have a chain of an even number of carbon atoms, from 4 to 28. Fatty 
acids are usually derived from triglycerides or phospholipids. When they are not attached 
to other molecules, they are known as "free" fatty acids. Fatty acids are important sources 
of fuel because, metabolized, they yield large quantities of ATP. Many cell types can use 
either glucose or fatty acids for this purpose. In particular, heart and skeletal muscle prefer 
fatty acids. The brain cannot use fatty acids as a source of fuel; it relies on glucose or  
ketone bodies.
Newborn  screening  includes  testing  for  a  panel  of  acylcarnitines.  In  some  cases,  an 
elevated level of a particular acylcarnitine may indicate the possibility of one of several  
different fatty acid oxidation disorders; the specific disorder cannot be determined without 
diagnostic further testing. It has been demonstrated that the following fatty acid oxidation 
disorders may be detected in newborn dried blood spot samples using a testing panel.
Fatty  acid  oxidation  disorders  are  inherited  in  an  autosomal  recessive  pattern,  which 
means two copies of a gene must be changed for a person to be affected with a fatty acid 
oxidation disorder.
Fatty acids with carbon chain lengths of primarily 18 carbons or less are metabolized in the 
mitochondria by a process known as β-oxidation [19]. They are transported through the 
cellular membrane into the cell cytosol and are translocated across the outer mitochondrial  
membrane to from fatty acyl-CoA thioesters. Each round of metabolism produces a single 
molecule of Acetyl-CoA.
Intermediates of mitochondrial β-oxidation or peroximal β-oxidation are important clinical 
diagnostic markers for many disorders of fatty acid and organic acis metabolism.These 
mitochondrial fatty acids can be found in blood and plasma and detected using methods 
such as MS/MS.
Several disorders in mitochondrial β-oxidation have been characterized and include very 
long-chain  acyl-CoA  dehydrogenase  (VLCAD)  deficiency,  medium-chain  acyl-CoA 
dehydrogenase  (MCADD)  deficiency,  short-chain  acyl-CoA  dehydrogenase  (SCAD) 
deficiency, multiple acyl-CoA dehydrogenase deficiency (MADD) etc. (Fig.7).
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Figure 7. Fatty Acid Oxidation Pathway.
1.1.3 MCADD
Medium chain acyl CoA dehydrogenase deficiency (MCADD) is an autosomal recessive 
disorder of beta-oxidation of fatty acids, which occurs in approximately 1 in 20,000 live 
births. MCADD generally presents clinically between the second month and second year 
of life, although presentation as early as two days old and as late as 6 years old has been 
noted  (**be  aware  that  asymptomatic  and  symptomatic  adults  are  now  also  being 
diagnosed, some after having their own MCADD children diagnosed or after an episode). 
MCAD  deficiency  occurs  primarily  in  Caucasians  of  northern  European  background. 
Parental consanguinity and recurrence in siblings is observed.
The enzymatic deficiency is of the medium chain acyl CoA dehydrogenase, one of four 
mitochondrial acyl-CoA dehydrogenases that carry out the initial dehyrdogenation step in  
the beta-oxidation cycle. MCAD deficiency impairs oxidation of dietary and endogenous 
fatty acids of medium chain length (6-12 carbon).
Clinical presentation is often triggered by a seemingly innocuous illness (like otitis media).  
The initiating event  is probably due to prolonged fasting,  which  may lead to  vomiting,  
lethargy,  coma, cardiopulmonary arrest, or sudden unexplained death. Symptoms often 
precede the onset of profound hypoglycemia and are probably related to high free fatty 
acid levels. Hypoglycemia occurs from an inability to meet gluconeogenic requirements 
during  fasting  despite  activation  of  an  alternate  pathway  of  substrate  production,  
proteolysis. Physical examination of the acutely ill child is remarkable for mild to moderate 
hepatomegaly. Some patients may also have demonstrable muscle weakness.
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Initial laboratory examination of blood may reveal hypoglycemia, mild metabolic acidosis, 
mild lactic acidosis, hyperammonemia, elevated BUN (Blood Urea Nitrogen), and high uric 
acid levels. Liver function studies are also usually elevated. Examination of the urine often 
shows inappropriately low or absent ketones.
Biochemical  testing  of  blood  and  urine  for  carnitine,  acylcarnitines,  acylglycines,  and 
organic  acids  is  diagnostic  for  this  disorder.  Low  serum  and  urine  carnitines  are 
consistently found in the untreated patient. A generalized dicarboxylic aciduria is noted 
characterized by elevation of suberylglycine and hexanoylglycine. Plasma or blood spot  
acylcarnitine  profiles  show  elevations  of  medium  chain  length  fatty  acid  derived 
acylcarnitines, especially octanoylcarnitine [20].
Without prior indication of metabolic disease, 20-25 percent of patients with this disease 
will die with their first episode of illness. 
Analysis of fibroblasts from individuals tested for the activity of medium chain acyl CoA 
dehydrogenase clearly reveal the affected individuals while heterozygous carriers for the  
disease usually have intermediate levels of activity, but are otherwise clinically and bio-
chemically unaffected. 
Detection of  mutations in the DNA of chromosome 1 in affected individuals allows for  
confirmation of  biochemical  testing and accurate detection of  asymptomatic  carriers in 
other family members. DNA analysis of postmortem tissue is possible when plasma and 
urine samples are not available, and has been diagnostic in fixed tissue over 20 years old.
Fundamental to the medical management of MCADD is to avoid fasting, particularly during 
periods of high metabolic stress, such as illness. Overnight fasts should last no longer than 
twelve hours, and infants should continue to receive nighttime or late evening feedings to  
reduce this period even further. High carbohydrate intake should be encouraged during 
illness, with initiation of intravenous glucose supplementation if the child is unsuccessful in 
keeping down fluids, or unable to take adequate oral feedings. The preventative efficiency 
of a low fat diet versus a normal fat diet is unclear, but high intake of long and medium 
chain fatty acids should be avoided.
Supplementation  with  oral  L-carnitine  at  100  mg/kg/day  has  been  associated  with  a 
reduction in the frequency and severity of episodes in many patients. We recommend that 
the dose be increased to 200 mg/kg/day during acute illness. The continued need for  
carnitine supplementation post puberty is uncertain, and has not been adequately studied. 
The addition of 1 - 3 tablespoons of food grade cornstarch mixed in liquid at bedtime to 
some infants has also helped to decrease the frequency of morning hypoglycemia.
It  is  imperative that,  on arrival  in  an emergency room while  lethargic,  10% glucose is 
started  immediately  following  blood  chemistry  sampling.  The  standard  of  emergency 
practice with the lethargic child is to use only normal saline. Several deaths have occurred 
because of this with MCAD deficient patients. The 2-3 hour delay, while waiting for results 
of chemistries, and receiving only saline deprives the child of the glucose that is critically  
needed. Several lawsuits are currently pending because of this. It is recommended that  
parents have written instructions in their wallets to present to emergency personnel  to 
prevent this catastrophe.
Prenatal  diagnosis  is  possible  through  amniocyte  culture.  In  vitro  probe  of  the  beta-
oxidation  pathway  or  enzyme  assay,  and DNA analysis  for  the  G985  (gene  ACADM) 
mutation in amniocytes or chorionic villi can also be helpful in the diagnosis of affected and 
carrier fetuses in pregnancies at risk where both parents carry that mutation. Most families 
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choose  to  test  the  infant  postnatally  during  the  neonatal  periods  since  prophylactic 
treatment of MCADD, pending test results, is safe. Prenatal supplementation of the mother  
of a potentially affected fetus with L-carnitine to improve fetal carnitine stores may be an 
effective prenatal treatment, ensuring adequate carnitine availability in the newborn period.
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1.2 MATERIALS AND METHODS
2.2.1 Expanded Newborn Screening programs
A pilot expanded newborn screening programme to detect inherited metabolic disorders by 
means of liquid  chromatography coupled with  tandem mass spectrometry (LC-MS/MS) 
began in the Campania region, southern Italy, in 2007. By October 2011, >23.753 dried 
blood samples on filter paper from 14 hospitals in the region had been screened in our 
laboratory.  Within this programme, we detected two cases of  Medium Chain acyl CoA 
Dehydrogenase (MCADD) deficiency, one case of β-ketothiolase Deficiency, one case of 
Short  Branched  Chain  Amino  acid  Deficiency,  two  cases  of  maternal  vitamin  B12 
deficiency, one case of Propionic aciduria, one case of Isovaleric aciduria, one case of 
Methymlonic aciduria and one case of Isobutirryl CoA Dehydrogenase Deficiency.
2.2.2 Sample preparation
From each dried blood filter card a 3 mm spot, containing 3.3 µL of blood, was punched 
and transferred into tubes, where 200 µL of methanol containing deuterated aminoacids 
and acylcarnitines standards was added. The standards were used to quantify aminoacids 
and acylcarnitine that are extracted into the methanol.
The  sample  were  vortexed  and  shaked  for  20  minutes.  After  that,  the  solvent  was 
evaporated  under  a  gentle  streem  of  N2.  The  most  common  method  for  extracted 
metabolite  preparation  requires  esterification  that  facilitates  ionization  and  improves 
sensitivity. The derivatization requires addition of 75 µL of acidified butanol for butyl esters 
formation. After incubation at 65° C for 25 minutes, the excess derivatization agent was 
removed under a gentle stream of N2. Just prior to MS/MS analysis the specimen was 
reconstituted in 300 µL of a solvent containing acetonitrile/water/formic acid (70:30:0,05 by 
volume) that assist in protonation and ionization [21].
2.2.3 Acylcarnitines and amino acids profile
We describe below a clinical case of a newborn to whom is diagnosed a Medium-Chain 
Acyl CoA Dehydrogenase Deficiency at birth. The comparison between a normal profile of 
acylcarnitine and a profile referring to a child affected by MCADD highlights the anomalous 
concentrations of hesanoylcarnitine (C6), octanoylcarnitine (C8), decanoylcarnitine (C10) 
and decenoylcarnitine (C10:1), respectively observed at m/z ratio of 316, 344,372 and 370 
in the patient (Fig. 8-9).
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Figure 8. Comparison between a normal profile of acylcarnitine and a profil relating to a child affected by MCADD.
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Disorder Abbrev. MARKER
Propionyl CoA Carboxylase Deficiency PA C3
Methylmalonic Acidemia MMA C3, C4DC
Isovaleryl CoA Dehydrogenase Deficiency IVA C5
Short-branched chain acyl-CoA dehydrogenase 
deficiency SBCAD C5
Glutaryl CoA Dehydrogenase Deficiency Type I GA-I C5DC
Glutaric Acidemia Type II GA-II C4,C5,C6,C8,C10
3-Methylcrotonyl CoA Carboxylase Deficiency 3MCC C5OH
Mitochondrial Acetoacetyl CoA Thiolase Deficiency BKT C5:1, C5OH, C4OH
2-Methyl-3-Hydroxybutyryl CoA Dehydrogenase 
Deficiency MHBD C5:1, C5OH
Medium/Short Chain Hydroxylacyl CoA 
Dehydrogenase M/SCHAD C4OH, C6OH
Isobutyryl CoA Dehydrogense Deficiency IBD C4
Medium Chain Acyl-CoA Dehydrogenase Deficiency MCADD C6,C8,C10,C10:1
Short Chain Acyl-CoA Dehydrogenase Deficiency SCAD C4
Very Long Chain Acyl-CoA Dehydrogenase 
Deficiency VLCAD C14,C14:1,C14:2,C16:1
Carnitine Palmitoyltransferase Deficiency Type II CPT-II C16,C18:1,C18:2
 Figure 9.  The table shows the symptomatic markers of some diseases. In red are highlighted the acyl carnitines altered in cases of 
MCADD.
1.3 RESULTS AND DISCUSSION
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Immediately after the diagnosis, the patient underwent emergency therapy with glucose,  
after which the carnitine concentration decreased significantly as described in the figure 10 
where is shown the profile of acylcarnitine during therapy.
The results of therapy are evident:  LC-MS/MS analysis shows that C0 decreases from 
0.62 µmol/L to 0.2 µmol/L , the C8 decreases from 6.14 µmol/L to 0.98 µmol/L , the C10 
decreases from 0.60 µmol/L to 0,11 µmol/L and C10: 1 decreases from 0.51 µmol/L to  
0.25 µmol/L .
Subsequently, the newborn is subjected to long-term treatment with carnitine.
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Figure 10.  Comparison between a normal profile of acylcarnitine and a profil relating to a child affected by MCADD during teraphy with 
glucose.
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1.4 CONCLUSIONS
The biochemical and molecular analysis are extended to family members, and in this way, 
the  early detection allows not only to discover that the relatives of affected child were 
healthy carriers of the disease, heterozygous for the mutation, but also to discover that her 
brother, one year and three months old, was affected with the same pathology,  thereby 
allowing to save the baby treating him with proper medical care.
This result was obtained thanks to MS/MS technology. It offers a new vision to newborn-
screening programs that now have the ability to screen for 30 or more metabolic disorders 
in a single analysis from one small disk of dried blood in a few minutes. This approach was 
revealed a reliable method for the early diagnosis of different inborn errors of metabolism:  
amino acidemias, fatty-acid organic disorders and organic acidurias. Now it is possible to 
screen rapidly,  simultaneously,  and inexpensively many very rare disorders. Due to the 
robustness  of  tandem  MS  technology,  a  number  of  metabolic  disorders  with  unclear 
natural history have been added to the screening programs. The large increase in the 
number  of  inherited  metabolic  disorders  detectable  in  the  newborn  period  because of 
tandem MS screening greatly extends the possibilities of early, generally presymptomatic,  
diagnosis and treatment to minimize morbidity and mortality for many affected children.
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Chapter 3 
THERAPEUTIC DRUG MONITORING IN CML PATIENTS
INTRODUCTION
3.1 CHRONIC MYELOID LEUKEMIA
3.1.1 Clinical features
The  second  line  of  research,  concerning  the  development  of  analytical  methods  for 
qualitative and quantitative assessments of drugs in biological fluids, has focused primarily 
on the development of analytical methods for the assay of imatinib, a drug used to treat 
patients with chronic myeloid leukemia.
Chronic  myelogenous leukemia  (CML),  also  known  as chronic  myeloid  leukemia,  is  a 
myeloproliferative disorder characterized by increased proliferation of the granulocytic cell 
line without the loss of their capacity to differentiate. Consequently, the peripheral blood 
cell profile shows an increased number of granulocytes and their immature precursors, 
including occasional blast cells. The median age at presentation is 53 years, but all age 
groups, including children, are affected. Most patients also have thrombocytosis, which is 
consistent  with  the presence of  a defect  in a pluripotent  hematopoietic  stem cell.  The 
typical  symptoms at  presentation are fatigue,  anorexia,  and weight  loss,  but  about  40 
percent of patients are asymptomatic, and in these patients, the diagnosis is based solely  
on an abnormal blood count. The most common abnormality on physical examination is 
splenomegaly, which is present in up to half of patients.
CML progresses through 3 phases: 
- chronic
- accelerated
- blast
In  the  chronic  phase  of  disease,  mature  cells  proliferate;  in  the  accelerated  phase, 
additional  cytogenetic  abnormalities  occur;  in  the  blast  phase,  immature  cells  rapidly 
proliferate [22]. Approximately 85% of patients are diagnosed in the chronic phase and 
then progress to the accelerated and blast phases after 3-5 years.
3.1.2 Molecular pathophisiology
CML was the first malignancy to be linked to a clear genetic abnormality, the chromosomal 
translocation known as the Philadelphia chromosome. This chromosomal abnormality is so 
named because  it  was  first  discovered  and  described  in  1960  by  two  scientists  from 
Philadelphia,  Pennsylvania,  USA:  Peter  Nowell  of  the  University  of  Pennsylvania  and 
David Hungerford of Fox Chase Cancer Center.
In this translocation, parts of two chromosomes, the 9th and 22nd, switch places. As a 
result, part of the BCR ("breakpoint cluster region") gene from chromosome 22 is fused 
with the ABL (Ableson leukemia virus) gene on chromosome 9. This abnormal "fusion" 
gene generates a protein of 210 kDa or sometimes 185 kDa (Fig. 11). 
37
Recently, a larger, 230kDa BCR–ABL fusion protein was found in a subgroup of patients 
with CML who presented with a lower white-cell count than is usual for the disease and in 
whom progression to blast crisis was slow [23]. The fact that fusion proteins of different 
sizes can be correlated with different outcomes has led to laboratory studies of the biologic 
activity of the proteins. The results indicate that the 190-kDa BCR–ABL protein has greater 
activity as a tyrosine kinase and is a more potent oncogene than the 210-kDa protein,  
suggesting that the magnitude of the tyrosine kinase signal affects the expression of the 
disease [24] [25].
Figure 11. Structure of BCR-ABL fusion proteins.
Because abl  carries a domain that can add phosphate groups to  tyrosine residues (a 
tyrosine kinase), the bcr-abl fusion gene product is also a tyrosine kinase. 
The  fused  BCR-ABL  protein  interacts  with  the  interleukin-3  receptor  (also  known  as 
CD123 antigen),  that  is  a  molecule  found on cells  which  helps  transmit  the  signal  of  
interleukin-3, a soluble cytokine important in the immune system. The BCR-ABL transcript 
is continuously active and does not require activation by other cellular messaging proteins.  
In turn, BCR-ABL activates a cascade of proteins that control the cell cycle, speeding up 
cell  division.  Moreover,  the  BCR-ABL  protein  inhibits  DNA  repair,  causing  genomic 
instability  and  making  the  cell  more  susceptible  to  developing  further  genetic 
abnormalities. The action of the BCR-ABL protein is the pathophysiologic cause of chronic 
myelogenous leukemia.
3.1.3 Treatment
The goals of treatment are to achieve hematologic, cytogenetic, and molecular remission.  
Although a variety of medications have been used in CML, including myelosuppressive 
agents and interferon α,  the tyrosine kinase inhibitor Imatinib mesylate is currently the 
agent of choice because it can induce complete remissions in CML, confirming the central  
importance of bcr-abl as the cause of CML.
Other drugs in this category are playing increasingly important roles. However, allogeneic 
bone marrow transplantation is currently the only proven cure for CML.
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3.1.3.1 Imatinib mesylate
Imatinib (designated chemically as 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-
pyridinyl)-2-pyrimidinyl]amino]-phenyl]benzamide  methanesulfonate)  is  a  drug  used  to 
treat certain types of cancer. It  is currently marketed by Novartis as Gleevec (USA) or 
Glivec (Europe/Australia/Latin America) as its mesylate salt, Imatinib mesylate (INN). It is 
used  in  treating  chronic  myeloid  leukemia,  in  treating  gastrointestinal  stromal  tumors 
(GISTs) and some other diseases. Imatinib is the first member of a new class of agents 
that  act  by specifically inhibiting a certain  enzyme that  is  characteristic  of  a  particular  
cancer cell, rather than non-specifically inhibiting and killing all rapidly dividing cells, and  
served as a model for other targeted therapy modalities through tyrosine kinase inhibition.
It  is  a  competitive  inhibitor  of  the  Bcr-Abl  tyrosine  kinase,  a  constitutively  active 
oncoprotein involved in CML pathogenesis [26]. In CML, the tyrosine kinase enzyme ABL 
is locked in its activated form. It  induces the abnormal phenotypes of CML: excessive 
proliferation and high white blood cell count. Imatinib binds to the site of tyrosine kinase 
activity, and prevents its activity.
Imatinib  was  developed  by  rational  drug  design.  After  the  Philadelphia  chromosome 
mutation  and  hyperactive  bcr-abl  protein  were  discovered,  the  investigators  screened 
chemical  libraries  to  find  a  drug  that  would  inhibit  that  protein.  With  high-throughput 
screening, they identified 2-phenylaminopyrimidine. 
This  lead compound was  then tested and modified  by the  introduction  of  methyl  and 
benzamide groups to give it enhanced binding properties, resulting in Imatinib. Gleevec 
received FDA approval in May 2001.
Gleevec also holds the record for the drug with the fastest approval time by the FDA. 
According to Brian Druker, one of the developers of Imatinib, the biggest obstacle to being 
approved was the name of the drug. At that time, the drug was being called "Glivec", which 
is also the current spelling in most parts of the world. However, the United States Food 
and Drug Administration did not want  people to mispronounce "Glivec" as "GLIE-VEC" 
which  could  be  confused  with  a  diabetic  drug  at  the  time.  Therefore,  Novartis,  the 
pharmaceutical company who markets Gleevec, changed the name of "Glivec" to include 
two  "e's"  and  avoid  the  phonetic  confusion:  Gleevec.  Shortly  thereafter,  Gleevec  was 
approved by the FDA.
The  most  common  side  effects  include  weight  gain,  reduced  number  of  blood  cells 
(neutropenia,  thrombocytopenia,  anemia),  headache,  edema,  nausea,  rash,  and 
musculoskeletal pain.
Severe congestive cardiac failure is an uncommon but recognized side effect of Imatinib  
and mice treated with large doses of Imatinib show toxic damage to their myocardium [27].
If  Imatinib  is  used  in  prepubescent  children,  it  can  delay  normal  growth,  although  a 
proportion will experience catch-up growth during puberty [28].
Imatinib is rapidly absorbed when given by mouth, and is highly bioavailable: 98% of an 
oral  dose  reaches the  bloodstream.  Metabolism of  Imatinib  occurs  in  the  liver  and is 
mediated  by  several  isozymes  of  the  cytochrome  P450  system.  The  major  route  of 
elimination is in the bile and feces; only a small portion of the drug is excreted in the urine.  
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Most of Imatinib is eliminated as metabolites, only 25% is eliminated unchanged. The half-
lives of Imatinib and its main metabolite are 18 and 40 hours, respectively. It blocks the 
activity of Abelson cytoplasmic tyrosine kinase (ABL), c-Kit and the platelet-derived growth 
factor receptor (PDGFR). As an inhibitor of PDGFR, Imatinib appears to have utility in the  
treatment of a variety of dermatological diseases.
Mechanism of action of Imatinib is to function as a specific inhibitor of a number of tyrosine 
kinase enzymes. It occupies the TK active site, leading to a decrease in activity.
There  are  a large number of  TK enzymes in  the  body,  including  the insulin  receptor.  
Imatinib  is  specific  for  the  TK domain  in  abl  (the  Abelson  proto-oncogene),  c-kit  and 
PDGF-R (platelet-derived growth factor receptor).
In CML, the Philadelphia chromosome leads to a fusion protein of abl with bcr (breakpoint  
cluster  region),  termed  bcr-abl.  As  this  is  now a  constitutively  active  tyrosine  kinase, 
Imatinib is used to decrease bcr-abl activity.
The active sites of tyrosine kinases each have a binding site  for ATP. The enzymatic 
activity catalyzed by a tyrosine kinase is the transfer of the terminal phosphate from ATP 
to  tyrosine  residues  on  its  substrates,  a  process  known  as  protein  tyrosine 
phosphorylation. Imatinib works by binding close to the ATP binding site of bcr-abl, locking 
it in a closed or self-inhibited conformation, and therefore inhibiting the enzyme activity of  
the protein semi-competitively [29]. This fact explains why many BCR-ABL mutations can 
cause  resistance  to  Imatinib  by  shifting  its  equilibrium  toward  the  open  or  active 
conformation [30].
Imatinib is quite selective for bcr-abl. It does also inhibit other targets as c-kit and PDGF-R, 
but no other known tyrosine kinases. Imatinib also inhibits the abl protein of non-cancer 
cells but cells normally have additional redundant tyrosine kinases which allow them to 
continue to function even if abl tyrosine kinase is inhibited. Some tumor cells, however, 
have a dependence on bcr-abl. Inhibition of the bcr-abl tyrosine kinase also stimulates its  
entry in to the nucleus, where it  is  unable to perform any of its normal anti-apoptopic  
functions  [31].  Imatinib  plasma monitoring  is  important  for  treatment  because patients 
being treated can acquire resistance to the drug after 4-5 years of treatment; in case of  
failure of the therapy and occurrence of severe adverse events it is important to intervene 
promptly by adjusting the dose of imatinib or making other therapeutic choices based on 
the administration of II generation drugs such as nilotinib and dasatinib.
3.1.3.2 Nilotinib
Nilotinib  (designated  chemically  as  4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-
(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide)  is  a  selective 
Bcr/Abl tyrosine kinase inhibitor. This type of medicine is used in treatment of leukemia 
(specifically CML). Nilotinib is considered a "second-generation" Bcr/Abl tyrosine kinase 
inhibitor, building on the success of Imatinib. Because many patients develop resistance to 
Imatinib, there is excitement about Nilotinib.  A recent research report concluded it  has 
"great potential" for leukemia treatment. The "binding mode" of Nilotinib is energetically  
more  favorable  than that  of  Imatinib.  This  results  in  a  more selective  targeting  of  the 
malignancy. Nilotinib has been shown to have an approximately 20-fold increased potency 
in kinase and proliferation assays compared to Imatinib. This is especially important for 
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older  patients  and they tend  to  have  trouble  tolerating  Imatinib  treatment.  The higher 
dosages required for Imatinib make it tough; Nilotinib is hoped to alleviate the side effects 
but still be effective [32].
3.2 MATERIALS AND  METHODS
3.2.1 Materials
Imatinib  mesylate,  the  internal  standard  for  LC-MSMS  (imatinib-D8)  and  the  internal  
standard  for  HPLC-UV methods  (nilotinib)  were  kindly  given  by  Novartis  Pharma  AG 
(Basel,  Switzerland);  HPLC grade  acetonitrile  and  methanol  were  purchased  from JT 
Baker (Mallinckrodt Baker B.V., Deventer, Netherlands) or VWR International (Milan, Italy). 
Formic  acid  was  purchased  from  JT  Baker  (Mallinckrodt  Baker  B.V.,  Deventer,  
Netherlands);  triethylamine  was  purchased  from  VWR  International  (Milan,  Italy). 
Ammonium formate 10 M solution was purchased from Sigma-Aldrich (Milan, Italy);  all  
solutions were prepared using highly purified water produced by a Millipore Milli-RO/Milli-Q 
system (Millipore, Bedford, Ma, USA) or by a Milli-DI system coupled with a Synergy 185 
system (Millipore, Bedford, Ma, USA) and used without any further purification. 
3.2.2 Patients
 
Chronic phase myeloid leukemia patients included in this study were treated daily with  
200, 300, 400, 600 and 800 mg dose of imatinib for a minimum of 3 month. Plasma from 
the 162 patients and healthy donors was received by Azienda Ospedaliero-Universitaria 
“San Luigi Gonzaga” (Orbassano, Italy) or by Azienda Ospedaliera Universitaria “Federico 
II” (Naples, Italy) and CEINGE Biotecnologie Avanzate, s.c.a r.l. (Naples, Italy).
Plasma samples were divided in two aliquots: one aliquot was analyzed by HPLC-UV in 
Orbassano and the other one was analyzed by LC-MSMS in Naples. Samples were stored 
at -20°C until analysis. Analyses were performed within two months from their arrival in 
laboratory.
3.2.3 Calibrators and quality controls preparation
LC-MS/MS stock solution of imatinib was prepared at a final concentration of 1 mg/mL in 
methanol and stored at -20°C.  The stability of stored imatinib solution was measured in 
triplicates during two months period. No significant differences were noted. Stock solution 
was then added to 200 μL of human plasma from healthy donor (calibrators) to produce 
final concentration of 78, 157, 313, 625, 1250, 2500, 5000 ng/mL. 100 μL of a 500 ng/mL 
solution of  internal  standard (imatinib-D8) in  methanol  were  added to  200 μL of  each 
calibrator and to 200 μL of patient plasma. To measure inter and intra assay variability, we 
used quality  controls  (QC) prepared as previously  described calibrators  at  an imatinib 
concentration of 50, 500 and 5000ng/mL.
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Proteins were precipitated by adding 500 μL of acetonitrile to each tube. The samples 
were then vortexed for 30 s and centrifuged at 10.000 g for 10 min. The suvranatants were 
transferred in 1.5mL vials and evaporated under a nitrogen stream at 45° C. Sample were  
reconstituted in 200 μL of Acetonitrile/Water MilliQ (10:90, v/v),  vortexed briefly,  diluted 
1:20. Finally 5 μL were injected into the LC-MS/MS system. 
For  HPLC-UV  method,  imatinib  was  added  to  healthy  donor  blank  plasma  to  obtain 
calibrators with concentrations of 50, 100, 500, 1000, 2500, and 5000 ng/mL. Nilotinib was 
used as internal standard (IS). Working solutions of IS were made at 50g/ml in methanol 
and used immediately. 50μL of IS were added to 500μL of each calibrator and to 500μL of 
patient plasma. 
Imatinib was extracted from plasma by protein precipitation: 750μL of acetonitrile/methanol  
(50:50)  were  added  to  each  sample.  Samples  were  then  vortexed  for  30s  and  then 
centrifuged at 12,000g for 10 min. 800μL of supernatant were transferred into HPLC vials 
[33-34]. 
HPLC and LC-MSMS analyses were performed in duplicate and all procedure steps were  
carried out at room temperature. 
3.2.4 HPLC-UV and LC-MS/MS methods
The  HPLC-UV  analyses  were  performed  on  a  VWR-Hitachi  system  (LaChrom  Elite) 
equipped with autosampler, spectrophotometer, and heated column compartment. 20μL of 
each described sample were injected. The chromatographic separation was achieved on a 
HyPurity 150x4.6mm, 3μm C18 reversed-phase narrowbore column (Superchrom, Milan, 
Italy)  preceded  by  a  SecurityGuard  Cartridges  4.0x3.0mm  C18  guard  column 
(Phenomenex, Castel Maggiore, Italy). The mobile phase was composed by 40% solvent 
A (Water:Methanol:Triethylamine/72.5:25:2.5,  pH 9.3),  20% methanol,  40% acetonitrile. 
The  flow  rate  was  0.5ml/min  at  35°C  and  the  eluate  was  monitored  at  267  nm. 
Chromatogram processing and data acquisition were performed by using the EzChrom 
Elite software.
The LC-MSMS analysis were performed on an Applied Biosystems MDS Sciex API 4000 
Triple–Quadrupole  Mass  Spectrometer  equipped  with  TurboIonSpray  source  (Applied 
Biosystems/Sciex,  Toronto,  Canada)  and  coupled  with  the  Agilent  1100  series  HPLC 
instrument  (Agilent  Technologies,  Waldbronn,  Germany).  5μL  of  the  each  described 
sample were injected into LC column. Chromatographic separations were performed on an 
Xterra RP18 column (2.1x100 mm, 5 μm, Waters, Milford, MA, USA) using water/formic 
acid 0.05% (v/v), ammonium formiate 4mM (A) and acetonitrile/formic acid 0.05% (v/v) (B) 
as  eluent.  A  gradient  was  delivered  at  300µL/min  starting  from 1% phase  B;  it  was 
maintained for 3min at 1% phase B and then raised to 25% in 7 min and to 100% in 2 min;  
and  then  an  isocratic  wash  of  100%  B  was  held  for  4  min  before  the  column  was 
equilibrated back to the initial condition in 2 min. The total analysis time was 18 min. 
The source temperature (at set-point) was 550°C with 5300 V applied as the ion spray 
voltage. All data were acquired in positive-selected reaction monitoring (SRM) to monitor 
m/z 494.3 > 394.2 transition for imatinib and m/z 502.4 > 394.2 transition for the internal  
standard (Fig. 12).
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Figure 12. Correlation between measurements obtained with HPLC-UV (X-axis) and LC-MSMS method (Y-axis) on total set of patient 
plasma samples (A), on plasma samples from patients treated by 200mg/daily (B), 300mg/daily (C), 400mg/daily (D), 
600mg/daily (E) and 800mg/daily (F) of imatinib.
The data were processed using the Analyst 1.4.2 software (Applied Biosystems/Sciex).
The  linearity  of  method  was  determined  by  performing  calibration  curves  using  7 
concentrations as previously described. 
The calibration curves of both methods were generated using the results of the calibration 
samples by linear least-squares regression analysis  according to the equation y=a+bx,  
where  y  was  the  peak–area  ratio  of  substance  to  internal  standard,  x  was  the 
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concentration of analyte in the calibration sample, a was the intercept, and b was the slope 
of the regression line. 
A weighted (1/x2) linear least-squares regression was used. Subsequently, concentrations 
of the quality control (QC) samples were calculated from the regression equation of the 
calibration curve.
3.2.5 Bland –Altman plot
The  Bland  and  Altman  plot  is  a  statistical  method  to  compare  two  measurements 
techniques  in  clinical  chemistry.  The plot  represents  a  graphical  method  in  which  the 
differences (or alternatively the ratios) between the two techniques are plotted against the 
average of the difference of the two techniques. If the differences between measurements 
using the two assay methods lie within the limits of agreement of the Bland–Altman test 
95% of the time, this indicates that the two methods are not producing different results  
[35].
3.2.6 Real time quantitative PCR
Real time quantitative PCR (RQ-PCR) provides the best monitoring strategy for patients 
with Chronic Myeloid Leukemia. To assess molecular responses, total RNA was extracted 
from  peripheral  blood  samples  and  the  amount  of  BCR-ABL  fusion  transcript  was 
quantified with respect to BCR transcript via RT-QPCR (Taqman assay) and expressed as 
a  log  ratio  [36].  The RQ-PCR method used TaqMan probes and the  7700 Sequence 
Detection  System  (Applied  Biosystems,  Foster  City,  CA).  RQ-PCR  analysis  with 
hybridization probe uses two juxtaposed sequence-specific  probes,  one labeled with  a 
donor  fluorochrome  (eg  FAM)  at  the  3’  end  and  the  other  labeled  with  an  acceptor 
fluorochrome at  its  5’  end.  Both  probes  should  hybridize  to  closely  juxtaposed  target  
sequences on the amplified DNA fragment, thereby bringing the two fluorochromes into 
close proximity (i.e. within 1–5 nucleotides). Upon excitation of the donor fluorochrome,  
light with a longer wavelength will be emitted. When the two fluorochromes are in close 
proximity, the emitted light of the donor fluorochrome will excite the acceptor fluorochrome. 
Clinical  applicability  of  MRD  (Minimal  Residual  Disease)  detection  in  hematologic 
malignancies process referred to as fluorescence resonance energy transfer. This results  
in the emission of fluorescence, which can be detected during the annealing phase and 
the first part of the extension phase of the PCR reaction.
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3.3 RESULTS AND DISCUSSION
The doctorate was conducted in a laboratory included in the project EUTOS imatinib BLT 
(Blood Level  Testing) as reference center in  central  and southern Italy  and islands to  
evaluate plasma imatinib concentrations.
Below, it  is  described the validation of methods used for the determination of imatinib 
plasma levels in CML patients. We used HPLC-UV and LC-MSMS. Application of these 
methods in monitoring follow-up of CML patients is also described.
The selected chromatographic conditions were set in order to speed-up the running time 
(18min) since specificity is provided by the MS/MS measurement. Sample dilution rate and 
injection volume (5 μL) were selected in order to avoid overloading the chromatographic  
column even after a high number of sample injections. The injection sample volume was 
selected after several trials with different injection volumes. 
A validation of the LC-MS/MS method was performed in human plasma sample. The linear 
regression of the peak area ratios versus concentrations was fitted over  concentration 
range of 78-5000 ng/. The method exhibits a regression equation y = 0.00408 x + 0.174 
and a correlation coefficient >0.995. Considering all the examined samples, discrepancies 
between expected values and measured values were within 10 %. In order to assess the 
robustness  of  the  method,  intraassay  variability  was  established  by  performing  6 
independent analyses of QC samples (50, 500 and 5000 ng/ml) during the same day. To 
establish interassay variation, QC samples were measured on six different days. Intra and 
interassay variability  are  reported  in  table  1.  All  the  estimated coefficient  of  variability 
(CVs) was below 10%, thereby demonstrating the reliability of the methodology. 
To determine the extraction recovery of imatinib non processed samples were prepared in 
mobile phase solution at concentrations corresponding to those used for the calibration 
curve  in  plasma.  The  recovery  was  determinate  calculating  the  ratio  of  the  slope  of 
processed versus unprocessed calibration curve. The mean recovery value was 70%.
Validation  of  HPLC-UV method  was  previously  performed and  data  are  reported  in  a 
previous publication [37] and summarized in Table 1.
Table 1. Intra and inter day variability
LC MSMS HPLC-UV
 50 ng/mL 500 ng/mL 5000 ng/mL 50 ng/mL 500 ng/mL 5000 ng/mL
Intra assay 
variability 
n=6 50.3 ± 3.3 496.5 ± 5.8 5012.0 ± 39.5 68.3 ± 5.9 411.7 ± 5.5 4287.7 ± 26.6
CV% 6.5 1.2 0.8 8.6 1.3 0.6
Inter assay 
variability 
n=6 50.5 ± 3.7 493.8 ± 7.3 4978.7 ± 133.8 58.3 ± 11.6 537.8 ± 66.6 4988.2 ± 521.2
CV% 7.3 1.5 2.7 19.9 12.4 10.4
Accuracy% 101 99 100 77 89 93
A total of 162 patients were enrolled in this study, classified in five groups according to 
imatinib dose taken daily.  9 patients were having 200mg of drug daily,  29 were having 
300mg, 91 were having 400mg, 24 were having 600mg, and 9 were having 800mg. The 
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samples were analyzed in triplicates by applying both methods (HPLC-UV and LC-MSMS). 
The correlation coefficient between the two methods was calculated using the total set of  
data.  In  addition  the  correlation  coefficient  was  calculated  for  each  group  of  data 
corresponding to the five groups of patients. The correlation coefficients are showed in 
Figure  12.  Results  showed  no  significant  differences  between  data  obtained  by  both 
methods. We performed Bland–Altman analysis  to  compare HPLC-UV with  LC-MS/MS 
data. We plotted the difference between the methods against the averages of values from 
the two techniques, as showed in  Figure 13A. The statistical  analysis  showed a good 
agreement  with  a bias  value  of  88,  in  the range mean ±2 SD (-816.2 -  640.3).  After  
logarithmic transformation of data (Fig.  13B), the mean difference detected by the two 
Figure 13. Bland–Altman plot of the differences on imatinib measurements obtained with HPLC-UV and LC-MSMS as a function of their 
mean value (A). Logarithmic transformation of the Bland–Altman plot (B).
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Plasma of six selected patients was monitored on time detecting the imatinib plasma levels 
using LC-MSMS methods and the molecular response (MR) to evaluate the correlation 
between  two  analyses.  Data  reported  in  Table  2  show  that  the  LC-MSMS  analysis 
confirms the  results  of  molecular  response:  where  the  major  molecular  response was 
achieved the plasma imatinib concentration is around 1000ng/ml (REF); conversely the 
plasma  imatinib  concentration  is  lower  or  higher  than  threshold  value  in  absence  of  
response to therapy (patients 2 and 5). MR patients show imatinib concentration medium, 
median and range respectively 1346, 1275 and 836-1920 ng/mL. Conversely, the no-MMR 
patients show medium, median and range respectively 1877, 2470 and 430-3150 ng/mL.
During  the PhD course,  experiments  have  been  undertaken for  the identification  and 
quantification of  metabolites resulting  from biotransformation of  imatinib,  through  LC-
MS/MS analysis.  Studies  with radioactive  labeling have  showed  that imatinib  and its 
main metabolite (N-desmethyl) are together responsible for only 65% of the radioactivity in 
circle, then  the  rest of  the  radioactivity is  due to  a number  of minor  metabolites still 
poorly characterized.  For  this reason,  a method  was  developed for  determining 
simultaneously the imatinib parent drug and some its metabolites that may have relevance 
if bioactive. The monitoring of new biomarkers could allow the use of imatinib calibrated on 
individual metabolism, in order to maximize effectiveness and minimize adverse effects.
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Table 2. Follow up of selected patients 
Time  MR (X100) LC-MSMS (ng/mL) 
PATIENTS 1 
0 0.338 2470 
5 months 0.094 1360 
8 months 0.054 1800 
10 months 0.000   
PATIENTS 2 
0 0.605 839 
3 months 0.130 932 
6 months 0.040  
9 months 0.059   
PATIENTS 3 
0 0.009 1920 
1 months 0.009 1310 
4 months 0.013 836 
12 months 0.000   
PATIENTS 4 
0 0.172 3150 
2 months 0.077 924 
4 months 0.085 1600 
8 months 0.085   
PATIENTS 5 
0 48.000 430 
1 months 16.926 2660 
2 months 22.816 2660 
3 months 14.340   
PATIENTS 6 
0 0.100 1140 
1 months 0.047 1190 
5 months 0.124  
8 months 0.244   
 
The laboratory where PhD project was performed, is also included in the international 
protocol GINEMA (Italian Group for Haematological Diseases) CML 0408. The Protocol 
GINEMA CML 0408 is an experimental study of phase II,  for the first-line treatment of 
CML, BCR-ABL positive, with two tyrosine-kinase inhibitors, imatinib and nilotinib.
Nilotinib and imatinib don’t  are given together,  but according to a schedule rotation, 3 
months nilotinib, 3 months imatinib, for 24 months (core study), and for other 36 months 
(study extension) if the patient is interested to continue.
The nilotinib is given orally twice a day, for a total daily dose of 800 mg. Imatinib is given 
orally once daily with a dose of 400 mg. The primary objective of this project is to evaluate  
the correlation between drug response and the plasma level of drugs.  
For this purpose, in addition to developing a method for determination of imatinib, has also 
developed a LC-MS/MS method for the dosage of nilotinib. To date, 123 patients enrolled 
in the study, excluding 23 dropouts, all  patients have reached 12 months of treatment. 
After 30 days of treatment with nilotinib, patients have a plasma mean concentration of 
2438 ng/mL; at day 90 they have a mean concentration of 2625 ng/mL. At days 120 and 
180, patients have a mean concentration of imatinib, respectively 1265 and 1220 ng/mL. 
At 270 day, after 3 months of treatment with nilotinib, mean concentration is 2958 ng/mL 
and at day 360, mean concentration of imatinib is 1180 ng/mL. Optimal concentrations of  
nilotinib are not reported in the literature, while recent studies show that imatinib plasma 
concentrations  slightly  higher  than  1000  ng/mL  are  associated  with  cytogenetic  and 
molecular responses optimal. More than 600 assays were performed.
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3.4 CONCLUSIONS
A further objective of the project was to evaluate the correlation of two methods for the 
assay of imatinib plasma concentration: LC-MS/MS e HPLC-UV/VIS. Applying the method 
of  differences to  the dose results  of  the 162 samples analyzed by LC-MS/MS HPLC-
UV/VIS it is shown that the measurements lie within the limits of agreement and the two 
methods are, therefore, interchangeable.
Over the time, six patients were monitored detecting the plasma imatinib concentration 
using LC-MS/MS and molecular response (MR) to assess the relationship between the two 
analysis.  This  comparison  shows  that  the  LC-MS/MS  analysis  confirms  molecular 
response data: in case of major molecular response, there is a plasma concentration of 
imatinib  of  about  1000  ng/mL  (optimal  concentration),  instead,  in  absence  of  good 
response to therapy, there is an imatinib plasma concentration lower or higher than the 
optimal one.
The dosages of imatinib for the GIMEMA 0408 protocol, confirmed that, after a year of  
treatment with rotating doses of imatinib and nilotinib, imatinib mean concentration is 1180 
ng/mL (Table 3). This information is very encouraging because it gives strength to the best 
perspective of the nilotinib use: to use this next generation drug not when imatinib has 
failed, but using it before, in order to avoid treatment failures with imatinib and achieve 
long-term results better than using a single type of drug.
•AV concentration of NIL at 30 days: 2438 ng/mL range= 755-4121 ng/mL
•AV concentration of NIL at 90 days: 2625 ng/mL range= 820-4430 ng/mL
•AV concentration of IM at 120 days: 1265 ng/mL range= 636-1894 ng/mL
•AV concentration of IM at 180 days: 1220 ng/mL range= 545-1895 ng/mL
•AV concentration of NIL at 270 days: 2958 ng/mL range= 1227-4689 ng/mL
•AV concentration of IM at 360 days: 1180 ng/mL range= 399-1961 ng/mL
Table 3. After a year of treatment with rotating doses of imatinib and nilotinib, imatinib mean concentration is 1180 ng/mL.
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